{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:16:01Z","timestamp":1783332961000,"version":"3.54.6"},"reference-count":334,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40259-026-00787-9","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:03:53Z","timestamp":1781539433000},"page":"641-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1399-9813","authenticated-orcid":false,"given":"Matthew J.","family":"Slarve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Tkaczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Break","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Spellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"DiGiandomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"787_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"787_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-016249","volume":"10","author":"NR Naylor","year":"2025","unstructured":"Naylor NR, Hasso-Agopsowicz M, Kim C, et al. The global economic burden of antibiotic-resistant infections and the potential impact of bacterial vaccines: a modelling study. BMJ Glob Health. 2025;10:10. https:\/\/doi.org\/10.1136\/bmjgh-2024-016249.","journal-title":"BMJ Glob Health"},{"key":"787_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMp1215093","volume":"368","author":"B Spellberg","year":"2013","unstructured":"Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368:299\u2013302. https:\/\/doi.org\/10.1056\/NEJMp1215093.","journal-title":"N Engl J Med"},{"key":"787_CR4","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1021\/acsinfecdis.3c00189","volume":"9","author":"M Bergkessel","year":"2023","unstructured":"Bergkessel M, Forte B, Gilbert IH. Small-molecule antibiotic drug development: need and challenges. ACS Infect Dis. 2023;9:2062\u201371. https:\/\/doi.org\/10.1021\/acsinfecdis.3c00189.","journal-title":"ACS Infect Dis"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3934\/microbiol.2018.3.482","volume":"4","author":"WC Reygaert","year":"2018","unstructured":"Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4:482\u2013501. https:\/\/doi.org\/10.3934\/microbiol.2018.3.482.","journal-title":"AIMS Microbiol"},{"key":"787_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxaf012","volume":"3","author":"B Spellberg","year":"2025","unstructured":"Spellberg B, Gilbert DN, Baym M, et al. Sustainable solutions to the continuous threat of antimicrobial resistance. Health Aff Sch. 2025;3:qxaf012. https:\/\/doi.org\/10.1093\/haschl\/qxaf012.","journal-title":"Health Aff Sch"},{"key":"787_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/CMR.13.4.602","volume":"13","author":"MA Keller","year":"2000","unstructured":"Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13:602\u201314. https:\/\/doi.org\/10.1128\/CMR.13.4.602.","journal-title":"Clin Microbiol Rev"},{"key":"787_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep15553","volume":"5","author":"J Zhang","year":"2015","unstructured":"Zhang J, Yang F, Zhang X, et al. Protective efficacy and mechanism of passive immunization with polyclonal antibodies in a sepsis model of Staphylococcus aureus infection. Sci Rep. 2015;5:15553. https:\/\/doi.org\/10.1038\/srep15553.","journal-title":"Sci Rep"},{"key":"787_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37826-w","volume":"14","author":"M Ragonnet-Cronin","year":"2023","unstructured":"Ragonnet-Cronin M, Nutalai R, Huo J, et al. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy. Nat Commun. 2023;14:3334. https:\/\/doi.org\/10.1038\/s41467-023-37826-w.","journal-title":"Nat Commun"},{"key":"787_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47393-3","volume":"15","author":"C Liu","year":"2024","unstructured":"Liu C, Das R, Dijokaite-Guraliuc A, et al. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4\/5 infection. Nat Commun. 2024;15:3284. https:\/\/doi.org\/10.1038\/s41467-024-47393-3.","journal-title":"Nat Commun"},{"key":"787_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","volume":"361","author":"T-S Migone","year":"2009","unstructured":"Migone T-S, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361:135\u201344. https:\/\/doi.org\/10.1056\/NEJMoa0810603.","journal-title":"N Engl J Med"},{"key":"787_CR12","doi-asserted-by":"publisher","first-page":"5796","DOI":"10.1128\/AAC.01102-16","volume":"60","author":"BJ Yamamoto","year":"2016","unstructured":"Yamamoto BJ, Shadiack AM, Carpenter S, et al. Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre- and postexposure prophylaxis in animal models of inhalational anthrax. Antimicrob Agents Chemother. 2016;60:5796\u2013805. https:\/\/doi.org\/10.1128\/AAC.01102-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1602615.","journal-title":"N Engl J Med"},{"key":"787_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41579-021-00660-2","volume":"20","author":"SL Kordus","year":"2022","unstructured":"Kordus SL, Thomas AK, Lacy DB. Clostridioides difficile toxins: mechanisms of action and antitoxin therapeutics. Nat Rev Microbiol. 2022;20:285\u201398. https:\/\/doi.org\/10.1038\/s41579-021-00660-2.","journal-title":"Nat Rev Microbiol"},{"key":"787_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1146\/annurev-micro-011320-011321","volume":"74","author":"A Shen","year":"2020","unstructured":"Shen A. Clostridioides difficile spore formation and germination: new insights and opportunities for intervention. Annu Rev Microbiol. 2020;74:545\u201366. https:\/\/doi.org\/10.1146\/annurev-micro-011320-011321.","journal-title":"Annu Rev Microbiol"},{"key":"787_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.20","volume":"2","author":"WK Smits","year":"2016","unstructured":"Smits WK, Lyras D, Lacy DB, et al. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. https:\/\/doi.org\/10.1038\/nrdp.2016.20.","journal-title":"Nat Rev Dis Primers"},{"key":"787_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, Mu Y, Winston LG, et al. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382:1320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1910215.","journal-title":"N Engl J Med"},{"key":"787_CR18","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","volume":"73","author":"S Johnson","year":"2021","unstructured":"Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile Iifection in adults. Clin Infect Dis. 2021;73:e1029\u201344. https:\/\/doi.org\/10.1093\/cid\/ciab549.","journal-title":"Clin Infect Dis"},{"key":"787_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","volume":"38","author":"J Czepiel","year":"2019","unstructured":"Czepiel J, Dr\u00f3\u017cd\u017c M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38:1211\u201321. https:\/\/doi.org\/10.1007\/s10096-019-03539-6.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"787_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01242-2","author":"CH Chilton","year":"2025","unstructured":"Chilton CH, Viprey V, Normington C, et al. Clostridioides difficile pathogenesis and control. Nat Rev Microbiol. 2025. https:\/\/doi.org\/10.1038\/s41579-025-01242-2.","journal-title":"Nat Rev Microbiol"},{"key":"787_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/gut.2006.119016","volume":"56","author":"SC Numan","year":"2007","unstructured":"Numan SC, Veldkamp P, Kuijper EJ, et al. Clostridium difficile\u2010associated diarrhoea: bovine anti\u2010Clostridium difficile whey protein to help aid the prevention of relapses. Gut. 2007;56:888\u20139. https:\/\/doi.org\/10.1136\/gut.2006.119016.","journal-title":"Gut"},{"key":"787_CR22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/infdis\/jiu605","volume":"211","author":"JK Sponseller","year":"2015","unstructured":"Sponseller JK, Steele JA, Schmidt DJ, et al. Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J Infect Dis. 2015;211:1334\u201341. https:\/\/doi.org\/10.1093\/infdis\/jiu605.","journal-title":"J Infect Dis"},{"key":"787_CR23","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s40265-016-0673-1","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A. Bezlotoxumab: first global approval. Drugs. 2016;76:1793\u20138. https:\/\/doi.org\/10.1007\/s40265-016-0673-1.","journal-title":"Drugs"},{"key":"787_CR24","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1128\/IAI.00982-06","volume":"74","author":"GJ Babcock","year":"2006","unstructured":"Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006;74:6339\u201347. https:\/\/doi.org\/10.1128\/IAI.00982-06.","journal-title":"Infect Immun"},{"key":"787_CR25","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1128\/IAI.02897-14","volume":"83","author":"Z Yang","year":"2015","unstructured":"Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83:822\u201331. https:\/\/doi.org\/10.1128\/IAI.02897-14.","journal-title":"Infect Immun"},{"key":"787_CR26","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1128\/AAC.00974-16","volume":"60","author":"P Warn","year":"2016","unstructured":"Warn P, Thommes P, Sattar A, et al. Disease progression and resolution in rodent models of Clostridium difficile infection and impact of antitoxin antibodies and vancomycin. Antimicrob Agents Chemother. 2016;60:6471\u201382. https:\/\/doi.org\/10.1128\/AAC.00974-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR27","doi-asserted-by":"publisher","first-page":"18008","DOI":"10.1074\/jbc.M114.560748","volume":"289","author":"P Orth","year":"2014","unstructured":"Orth P, Xiao L, Hernandez LD, et al. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014;289:18008\u201321. https:\/\/doi.org\/10.1074\/jbc.M114.560748.","journal-title":"J Biol Chem"},{"key":"787_CR28","doi-asserted-by":"publisher","first-page":"e00139","DOI":"10.1128\/iai.00139-25","volume":"93","author":"HK Kroh","year":"2025","unstructured":"Kroh HK, Jensen JL, Wellnitz S, et al. Mouse monoclonal antibodies against Clostridioides difficile toxins TcdA and TcdB target diverse epitopes for neutralization. Infect Immun. 2025;93:e00139-e225. https:\/\/doi.org\/10.1128\/iai.00139-25.","journal-title":"Infect Immun"},{"key":"787_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/infdis\/jis669","volume":"207","author":"J Steele","year":"2013","unstructured":"Steele J, Mukherjee J, Parry N, Tzipori S. Antibody against TcdB, but Not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis. 2013;207:323\u201330. https:\/\/doi.org\/10.1093\/infdis\/jis669.","journal-title":"J Infect Dis"},{"key":"787_CR30","unstructured":"US FDA. FDA drug shortages. https:\/\/www.accessdata.fda.gov\/scripts\/drugshortages\/dsp_ActiveIngredientDetails.cfm?AI=Bezlotoxumab%20Injection&st=d. Accessed 24 Nov 2025."},{"key":"787_CR31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/infdis\/jis416","volume":"206","author":"AJ Marozsan","year":"2012","unstructured":"Marozsan AJ, Ma D, Nagashima KA, et al. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis. 2012;206:706\u201313. https:\/\/doi.org\/10.1093\/infdis\/jis416.","journal-title":"J Infect Dis"},{"key":"787_CR32","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.molimm.2009.01.026","volume":"46","author":"V Oganesyan","year":"2009","unstructured":"Oganesyan V, Damschroder MM, Woods RM, et al. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol. 2009;46:1750\u20135. https:\/\/doi.org\/10.1016\/j.molimm.2009.01.026.","journal-title":"Mol Immunol"},{"key":"787_CR33","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1093\/infdis\/jiaf423","volume":"232","author":"KA Mahool","year":"2025","unstructured":"Mahool KA, Nguyen E, Godfrey V, et al. Epitope conservation of AZD5148, a broadly neutralizing anti-toxin B monoclonal antibody, among diverse and global contemporary Clostridioides difficile isolates. J Infect Dis. 2025;232:e741\u201352. https:\/\/doi.org\/10.1093\/infdis\/jiaf423.","journal-title":"J Infect Dis"},{"key":"787_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1074\/jbc.M117.813428","volume":"293","author":"HK Kroh","year":"2018","unstructured":"Kroh HK, Chandrasekaran R, Zhang Z, et al. A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells. J Biol Chem. 2018;293:941\u201352. https:\/\/doi.org\/10.1074\/jbc.M117.813428.","journal-title":"J Biol Chem"},{"key":"787_CR35","doi-asserted-by":"publisher","first-page":"7073","DOI":"10.1073\/pnas.1500791112","volume":"112","author":"ME LaFrance","year":"2015","unstructured":"LaFrance ME, Farrow MA, Chandrasekaran R, et al. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. Proc Natl Acad Sci USA. 2015;112:7073\u20138. https:\/\/doi.org\/10.1073\/pnas.1500791112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"787_CR36","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature19799","volume":"538","author":"L Tao","year":"2016","unstructured":"Tao L, Zhang J, Meraner P, et al. Frizzled are colonic epithelial receptors for Clostridium difficile toxin B. Nature. 2016;538:350\u20135. https:\/\/doi.org\/10.1038\/nature19799.","journal-title":"Nature"},{"key":"787_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/cr.2014.169","volume":"25","author":"P Yuan","year":"2015","unstructured":"Yuan P, Zhang H, Cai C, et al. Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B. Cell Res. 2015;25:157\u201368. https:\/\/doi.org\/10.1038\/cr.2014.169.","journal-title":"Cell Res"},{"key":"787_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.1244","volume":"12","author":"C Tkaczyk","year":"2025","unstructured":"Tkaczyk C, Dayao D, Girouard D, et al. P-1055. Anti-toxin B neutralizing monoclonal antibody AZD5148 provides protection in a Clostridioides difficile gnotobiotic piglet model. Open Forum Infect Dis. 2025;12:ofae631.1244. https:\/\/doi.org\/10.1093\/ofid\/ofae631.1244.","journal-title":"Open Forum Infect Dis"},{"key":"787_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1013651","volume":"21","author":"FC Peritore-Galve","year":"2025","unstructured":"Peritore-Galve FC, Kroh HK, Shupe JA, et al. The monoclonal antibody AZD5148 confers broad protection against TcdB-diverse Clostridioides difficile strains in mice. PLoS Pathog. 2025;21:e1013651. https:\/\/doi.org\/10.1371\/journal.ppat.1013651.","journal-title":"PLoS Pathog"},{"key":"787_CR40","unstructured":"AstraZeneca. A phase I double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of AZD5148 in healthy adults. 2025. https:\/\/www.clinicaltrials.gov. Accessed 10 Nov 2025."},{"key":"787_CR41","unstructured":"AstraZeneca. A phase IIb, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in individuals 18 years of age and above. 2025. https:\/\/www.clinicaltrials.gov. Accessed 10 Dec 2025."},{"key":"787_CR42","unstructured":"IDSA. C. difficile 2021 focused update. https:\/\/www.idsociety.org\/practice-guideline\/clostridioides-difficile-2021-focused-update\/. Accessed 23 Apr 2026."},{"key":"787_CR43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJM199808203390806","volume":"339","author":"FD Lowy","year":"1998","unstructured":"Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520\u201332. https:\/\/doi.org\/10.1056\/NEJM199808203390806.","journal-title":"N Engl J Med"},{"key":"787_CR44","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","volume":"400","author":"KS Ikuta","year":"2022","unstructured":"Ikuta KS, Swetschinski LR, Aguilar GR, et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400:2221\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(22)02185-7.","journal-title":"Lancet"},{"key":"787_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac130","volume":"5","author":"LS Witt","year":"2022","unstructured":"Witt LS, Howard-Anderson JR, Jacob JT, Gottlieb LB. The impact of COVID-19 on multidrug-resistant organisms causing healthcare-associated infections: a narrative review. JAC Antimicrob Resist. 2022;5:dlac130. https:\/\/doi.org\/10.1093\/jacamr\/dlac130.","journal-title":"JAC Antimicrob Resist"},{"key":"787_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrmicro3161","volume":"12","author":"TJ Foster","year":"2014","unstructured":"Foster TJ, Geoghegan JA, Ganesh VK, H\u00f6\u00f6k M. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol. 2014;12:49\u201362. https:\/\/doi.org\/10.1038\/nrmicro3161.","journal-title":"Nat Rev Microbiol"},{"key":"787_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.semcdb.2017.04.003","volume":"72","author":"ES Seilie","year":"2017","unstructured":"Seilie ES, Bubeck Wardenburg J. Staphylococcus aureus pore-forming toxins: the interface of pathogen and host complexity. Semin Cell Dev Biol. 2017;72:101\u20136. https:\/\/doi.org\/10.1016\/j.semcdb.2017.04.003.","journal-title":"Semin Cell Dev Biol"},{"key":"787_CR48","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","volume":"12","author":"GYC Cheung","year":"2021","unstructured":"Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence. 2021;12:547\u201369. https:\/\/doi.org\/10.1080\/21505594.2021.1878688.","journal-title":"Virulence"},{"issue":"1","key":"787_CR49","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02272-14","volume":"6","author":"A Jenkins","year":"2015","unstructured":"Jenkins A, Diep BA, Mai TT, et al. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. MBio. 2015;6(1):e02272-14. https:\/\/doi.org\/10.1128\/mbio.02272-14.","journal-title":"MBio"},{"key":"787_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd.2017.23","volume":"16","author":"SW Dickey","year":"2017","unstructured":"Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017;16:457\u201371. https:\/\/doi.org\/10.1038\/nrd.2017.23.","journal-title":"Nat Rev Drug Discov"},{"key":"787_CR51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/infdis\/jis192","volume":"206","author":"ME Powers","year":"2012","unstructured":"Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. ADAM10 mediates vascular injury induced by Staphylococcus aureus \u03b1-hemolysin. J Infect Dis. 2012;206:352\u20136. https:\/\/doi.org\/10.1093\/infdis\/jis192.","journal-title":"J Infect Dis"},{"key":"787_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075103","volume":"8","author":"C Tkaczyk","year":"2013","unstructured":"Tkaczyk C, Hamilton MM, Datta V, et al. Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model. PLoS ONE. 2013;8:e75103. https:\/\/doi.org\/10.1371\/journal.pone.0075103.","journal-title":"PLoS ONE"},{"key":"787_CR53","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1128\/aac.02190-13","volume":"58","author":"L Hua","year":"2014","unstructured":"Hua L, Hilliard JJ, Shi Y, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother. 2014;58:1108\u201317. https:\/\/doi.org\/10.1128\/aac.02190-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR54","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1128\/aac.00710-16","volume":"60","author":"VTM Le","year":"2016","unstructured":"Le VTM, Tkaczyk C, Chau S, et al. Critical role of alpha-toxin and protective effects of its neutralization by a human antibody in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2016;60:5640\u20138. https:\/\/doi.org\/10.1128\/aac.00710-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR55","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02456-16","volume":"61","author":"BA Diep","year":"2017","unstructured":"Diep BA, Hilliard JJ, Le VTM, et al. Targeting alpha toxin to mitigate its lethal toxicity in ferret and rabbit models of Staphylococcus aureus necrotizing pneumonia. Antimicrob Agents Chemother. 2017;61:e02456-16. https:\/\/doi.org\/10.1128\/AAC.02456-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR56","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1128\/AAC.03918-14","volume":"59","author":"JJ Hilliard","year":"2015","unstructured":"Hilliard JJ, Datta V, Tkaczyk C, et al. Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother. 2015;59:299\u2013309. https:\/\/doi.org\/10.1128\/AAC.03918-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR57","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1128\/aac.00510-15","volume":"59","author":"L Hua","year":"2015","unstructured":"Hua L, Cohen TS, Shi Y, et al. MEDI4893* promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother. 2015;59:4526\u201332. https:\/\/doi.org\/10.1128\/aac.00510-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR58","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01020-16","author":"X-Q Yu","year":"2016","unstructured":"Yu X-Q, Robbie GJ, Wu Y, et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother. 2016. https:\/\/doi.org\/10.1128\/aac.01020-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR59","unstructured":"Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. The Lancet Infectious Diseases. https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(20)30995-6\/abstract. Accessed 5 Nov 2025."},{"key":"787_CR60","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.jmb.2013.02.008","volume":"425","author":"D Foletti","year":"2013","unstructured":"Foletti D, Strop P, Shaughnessy L, et al. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus \u03b1-hemolysin. J Mol Biol. 2013;425:1641\u201354. https:\/\/doi.org\/10.1016\/j.jmb.2013.02.008.","journal-title":"J Mol Biol"},{"key":"787_CR61","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s00134-018-5229-2","volume":"44","author":"B Fran\u00e7ois","year":"2018","unstructured":"Fran\u00e7ois B, Mercier E, Gonzalez C, et al. Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Med. 2018;44:1787\u201396. https:\/\/doi.org\/10.1007\/s00134-018-5229-2.","journal-title":"Intensive Care Med"},{"key":"787_CR62","unstructured":"Aridis Pharmaceuticals, Inc. A randomized double-blind placebo-controlled multicenter phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of ventilator-associated pneumonia (VAP) caused by S. aureus. 2023. https:\/\/www.clinicaltrials.gov. Accessed 6 Jul 2023."},{"key":"787_CR63","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/19420862.2014.985132","volume":"7","author":"H Rouha","year":"2014","unstructured":"Rouha H, Badarau A, Visram ZC, et al. Five birds, one stone: neutralization of \u03b1-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs. 2014;7:243\u201354. https:\/\/doi.org\/10.4161\/19420862.2014.985132.","journal-title":"MAbs"},{"key":"787_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41826-6","volume":"9","author":"L Stulik","year":"2019","unstructured":"Stulik L, Rouha H, Labrousse D, et al. Preventing lung pathology and mortality in rabbit Staphylococcus aureus pneumonia models with cytotoxin-neutralizing monoclonal IgGs penetrating the epithelial lining fluid. Sci Rep. 2019;9:5339. https:\/\/doi.org\/10.1038\/s41598-019-41826-6.","journal-title":"Sci Rep"},{"key":"787_CR65","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00350-19","volume":"63","author":"Z Magyarics","year":"2019","unstructured":"Magyarics Z, Leslie F, Bartko J, et al. Randomized, double-blind, placebo-controlled, single-ascending-dose study of the penetration of a monoclonal antibody combination (ASN100) targeting Staphylococcus aureus cytotoxins in the lung epithelial lining fluid of healthy volunteers. Antimicrob Agents Chemother. 2019;63:e00350-19. https:\/\/doi.org\/10.1128\/AAC.00350-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00160-22","volume":"37","author":"L Sauvat","year":"2024","unstructured":"Sauvat L, Verhoeven PO, Gagnaire J, et al. Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections. Clin Microbiol Rev. 2024;37:e00160-22. https:\/\/doi.org\/10.1128\/cmr.00160-22.","journal-title":"Clin Microbiol Rev"},{"key":"787_CR67","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.4049\/jimmunol.173.9.5704","volume":"173","author":"P-J Haas","year":"2004","unstructured":"Haas P-J, de Haas CJC, Kleibeuker W, et al. N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol. 2004;173:5704\u201311. https:\/\/doi.org\/10.4049\/jimmunol.173.9.5704.","journal-title":"J Immunol"},{"key":"787_CR68","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/ni1235","volume":"6","author":"SHM Rooijakkers","year":"2005","unstructured":"Rooijakkers SHM, Ruyken M, Roos A, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol. 2005;6:920\u20137. https:\/\/doi.org\/10.1038\/ni1235.","journal-title":"Nat Immunol"},{"key":"787_CR69","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/21505594.2017.1294297","volume":"9","author":"H Hoekstra","year":"2017","unstructured":"Hoekstra H, Romero Pastrana F, Bonarius HPJ, et al. A human monoclonal antibody that specifically binds and inhibits the staphylococcal complement inhibitor protein SCIN. Virulence. 2017;9:70\u201382. https:\/\/doi.org\/10.1080\/21505594.2017.1294297.","journal-title":"Virulence"},{"key":"787_CR70","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/toxins11030178","volume":"11","author":"T Krakauer","year":"2019","unstructured":"Krakauer T. Staphylococcal superantigens: pyrogenic toxins induce toxic shock. Toxins. 2019;11:178. https:\/\/doi.org\/10.3390\/toxins11030178.","journal-title":"Toxins"},{"key":"787_CR71","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1084\/jem.180.2.615","volume":"180","author":"AR Hamad","year":"1994","unstructured":"Hamad AR, Herman A, Marrack P, Kappler JW. Monoclonal antibodies defining functional sites on the toxin superantigen staphylococcal enterotoxin B. J Exp Med. 1994;180:615\u201321. https:\/\/doi.org\/10.1084\/jem.180.2.615.","journal-title":"J Exp Med"},{"key":"787_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/1476-8518-8-9","volume":"8","author":"B Drozdowski","year":"2010","unstructured":"Drozdowski B, Zhou Y, Kline B, et al. Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B. J Immune Based Ther Vaccines. 2010;8:9. https:\/\/doi.org\/10.1186\/1476-8518-8-9.","journal-title":"J Immune Based Ther Vaccines"},{"key":"787_CR73","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/infdis\/jiu198","volume":"210","author":"AK Varshney","year":"2014","unstructured":"Varshney AK, Wang X, MacIntyre J, et al. Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin. J Infect Dis. 2014;210:973\u201381. https:\/\/doi.org\/10.1093\/infdis\/jiu198.","journal-title":"J Infect Dis"},{"key":"787_CR74","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1365-2249.1999.01061.x","volume":"118","author":"M Verdrengh","year":"1999","unstructured":"Verdrengh M, Kum W, Chow A, Tarkowski A. The effect of site-specific monoclonal antibodies directed to toxic shock syndrome toxin-1 in experimental Staphylococcus aureus arthritis. Clin Exp Immunol. 1999;118:268\u201370. https:\/\/doi.org\/10.1046\/j.1365-2249.1999.01061.x.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"787_CR75","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1128\/iai.68.6.3261-3268.2000","volume":"68","author":"LTY Pang","year":"2000","unstructured":"Pang LTY, Kum WWS, Chow AW. Inhibition of Staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody. Infect Immun. 2000;68(6):3261\u20138. https:\/\/doi.org\/10.1128\/iai.68.6.3261-3268.2000.","journal-title":"Infect Immun"},{"key":"787_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-022-00760-8","volume":"22","author":"M Soezi","year":"2022","unstructured":"Soezi M, Piri-Gavgani S, Ghanei M, et al. Identification of a novel fully human anti-toxic shock syndrome toxin (TSST)-1 single-chain variable fragment antibody averting TSST-1-induced mitogenesis and cytokine secretion. BMC Biotechnol. 2022;22:31. https:\/\/doi.org\/10.1186\/s12896-022-00760-8.","journal-title":"BMC Biotechnol"},{"key":"787_CR77","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.GPP3-0046-2018","author":"TJ Foster","year":"2019","unstructured":"Foster TJ. Surface proteins of Staphylococcus aureus. Microbiol Spectr. 2019. https:\/\/doi.org\/10.1128\/microbiolspec.GPP3-0046-2018.","journal-title":"Microbiol Spectr"},{"key":"787_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002307","volume":"7","author":"M McAdow","year":"2011","unstructured":"McAdow M, Kim HK, DeDent AC, et al. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog. 2011;7:e1002307. https:\/\/doi.org\/10.1371\/journal.ppat.1002307.","journal-title":"PLoS Pathog"},{"key":"787_CR79","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.vaccine.2004.08.015","volume":"22","author":"JM Patti","year":"2004","unstructured":"Patti JM. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine. 2004;22:S39-43. https:\/\/doi.org\/10.1016\/j.vaccine.2004.08.015.","journal-title":"Vaccine"},{"key":"787_CR80","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1128\/AAC.00096-06","volume":"50","author":"JJ Weems","year":"2006","unstructured":"Weems JJ, Steinberg JP, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006;50:2751\u20135. https:\/\/doi.org\/10.1128\/AAC.00096-06.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR81","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ebiom.2016.09.027","volume":"13","author":"VK Ganesh","year":"2016","unstructured":"Ganesh VK, Liang X, Geoghegan JA, et al. Lessons from the crystal structure of the S. aureus surface protein clumping factor A in complex with tefibazumab, an inhibiting monoclonal antibody. EBioMedicine. 2016;13:328\u201338. https:\/\/doi.org\/10.1016\/j.ebiom.2016.09.027.","journal-title":"EBioMedicine"},{"key":"787_CR82","doi-asserted-by":"publisher","first-page":"e421","DOI":"10.1093\/infdis\/jiaf357","volume":"232","author":"C Tkaczyk","year":"2025","unstructured":"Tkaczyk C, Keren-Kaplan T, Gamson A, et al. Structure of ClfA002 in complex with neutralizing antibody AZD7745 provides insight into its broad neutralization mechanism in Staphylococcus aureus infection. J Infect Dis. 2025;232:e421\u201330. https:\/\/doi.org\/10.1093\/infdis\/jiaf357.","journal-title":"J Infect Dis"},{"key":"787_CR83","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00629-17","volume":"61","author":"C Tkaczyk","year":"2017","unstructured":"Tkaczyk C, Kasturirangan S, Minola A, et al. Multimechanistic monoclonal antibodies (MAbs) targeting Staphylococcus aureus alpha-toxin and clumping factor A: activity and efficacy comparisons of a MAb combination and an engineered bispecific antibody approach. Antimicrob Agents Chemother. 2017;61:e00629-17. https:\/\/doi.org\/10.1128\/AAC.00629-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR84","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1074\/jbc.M114.603712","volume":"290","author":"MJ Borrok","year":"2015","unstructured":"Borrok MJ, Wu Y, Beyaz N, et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem. 2015;290:4282\u201390. https:\/\/doi.org\/10.1074\/jbc.M114.603712.","journal-title":"J Biol Chem"},{"key":"787_CR85","unstructured":"AstraZeneca. A phase I, IIa randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end-stage kidney disease receiving hemodialysis through a central venous catheter. 2025. https:\/\/www.clinicaltrials.gov. Accessed 30 Dec 2024."},{"key":"787_CR86","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02197-25","volume":"16","author":"B Banerjee","year":"2025","unstructured":"Banerjee B, Emolo C, Shi M, et al. Inhibitory activities of monoclonal antibodies against Staphylococcus aureus clumping factor A. MBio. 2025;16:e02197-25. https:\/\/doi.org\/10.1128\/mbio.02197-25.","journal-title":"MBio"},{"issue":"4","key":"787_CR87","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1128\/IAI.74.4.2145-2153.2006","volume":"74","author":"AC Schaffer","year":"2006","unstructured":"Schaffer AC, Solinga RM, Cocchiaro J, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun. 2006;74(4):2145\u201353. https:\/\/doi.org\/10.1128\/IAI.74.4.2145-2153.2006.","journal-title":"Infect Immun"},{"key":"787_CR88","doi-asserted-by":"publisher","first-page":"39837","DOI":"10.1074\/jbc.M005297200","volume":"275","author":"L Visai","year":"2000","unstructured":"Visai L, Xu Y, Casolini F, et al. Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate. J Biol Chem. 2000;275:39837\u201345. https:\/\/doi.org\/10.1074\/jbc.M005297200.","journal-title":"J Biol Chem"},{"key":"787_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190537","volume":"13","author":"AK Varshney","year":"2018","unstructured":"Varshney AK, Kuzmicheva GA, Lin J, et al. A natural human monoclonal antibody targeting Staphylococcus protein A protects against Staphylococcus aureus bacteremia. PLoS ONE. 2018;13:e0190537. https:\/\/doi.org\/10.1371\/journal.pone.0190537.","journal-title":"PLoS ONE"},{"key":"787_CR90","doi-asserted-by":"publisher","first-page":"828","DOI":"10.4049\/jimmunol.103.4.828","volume":"103","author":"G Kronvall","year":"1969","unstructured":"Kronvall G, Williams RC Jr. Differences in anti-protein A activity among IgG Subgroups. J Immunol. 1969;103:828\u201333. https:\/\/doi.org\/10.4049\/jimmunol.103.4.828.","journal-title":"J Immunol"},{"key":"787_CR91","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1432-1033.1986.tb09625.x","volume":"156","author":"T Moks","year":"1986","unstructured":"Moks T, Abrahms\u00e9n L, Nilsson B, et al. Staphylococcal protein A consists of five IgG-binding domains. Eur J Biochem. 1986;156:637\u201343. https:\/\/doi.org\/10.1111\/j.1432-1033.1986.tb09625.x.","journal-title":"Eur J Biochem"},{"key":"787_CR92","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.4049\/jimmunol.142.8.2778","volume":"142","author":"EH Sasso","year":"1989","unstructured":"Sasso EH, Silverman GJ, Mannik M. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J Immunol. 1989;142:2778\u201383.","journal-title":"J Immunol"},{"key":"787_CR93","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20020552","volume":"197","author":"CS Goodyear","year":"2003","unstructured":"Goodyear CS, Silverman GJ. Death by a B cell superantigen. J Exp Med. 2003;197:1125\u201339. https:\/\/doi.org\/10.1084\/jem.20020552.","journal-title":"J Exp Med"},{"key":"787_CR94","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.vaccine.2014.11.051","volume":"33","author":"V Thammavongsa","year":"2015","unstructured":"Thammavongsa V, Rauch S, Kim HK, et al. Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus. Vaccine. 2015;33:523\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.051.","journal-title":"Vaccine"},{"key":"787_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149460","volume":"11","author":"Y Yang","year":"2016","unstructured":"Yang Y, Qian M, Yi S, et al. Monoclonal antibody targeting Staphylococcus aureus surface protein A (SasA) protect against Staphylococcus aureus sepsis and peritonitis in mice. PLoS ONE. 2016;11:e0149460. https:\/\/doi.org\/10.1371\/journal.pone.0149460.","journal-title":"PLoS ONE"},{"key":"787_CR96","doi-asserted-by":"publisher","first-page":"22992","DOI":"10.1073\/pnas.2003621117","volume":"117","author":"X Chen","year":"2020","unstructured":"Chen X, Shi M, Tong X, et al. Glycosylation-dependent opsonophagocytic activity of staphylococcal protein A antibodies. Proc Natl Acad Sci USA. 2020;117:22992\u20133000. https:\/\/doi.org\/10.1073\/pnas.2003621117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"787_CR97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114478119","volume":"119","author":"X Chen","year":"2022","unstructured":"Chen X, Schneewind O, Missiakas D. Engineered human antibodies for the opsonization and killing of Staphylococcus aureus. Proc Natl Acad Sci USA. 2022;119:e2114478119. https:\/\/doi.org\/10.1073\/pnas.2114478119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"787_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1057","volume":"3","author":"T Huynh","year":"2016","unstructured":"Huynh T, Stecher M, Mckinnon J, et al. Safety and tolerability of 514G3, a true human anti-protein A monoclonal antibody for the treatment of S. aureus bacteremia. Open Forum Infect Dis. 2016;3:1354. https:\/\/doi.org\/10.1093\/ofid\/ofw172.1057.","journal-title":"Open Forum Infect Dis"},{"key":"787_CR99","doi-asserted-by":"publisher","first-page":"799","DOI":"10.5301\/ijao.5000030","volume":"34","author":"G Pietrocola","year":"2011","unstructured":"Pietrocola G, Arciola CR, Rindi S, et al. Toll-like receptors (TLRs) in innate immune defense against Staphylococcus aureus. Int J Artif Organs. 2011;34:799\u2013810. https:\/\/doi.org\/10.5301\/ijao.5000030.","journal-title":"Int J Artif Organs"},{"key":"787_CR100","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1128\/AAC.01565-08","volume":"53","author":"LE Weisman","year":"2009","unstructured":"Weisman LE, Thackray HM, Garcia-Prats JA, et al. Phase 1\/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2009;53:2879\u201386. https:\/\/doi.org\/10.1128\/AAC.01565-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR101","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1517\/14712598.2015.1019857","volume":"15","author":"M Patel","year":"2015","unstructured":"Patel M, Kaufman DA. Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants. Expert Opin Biol Ther. 2015;15:595\u2013600. https:\/\/doi.org\/10.1517\/14712598.2015.1019857.","journal-title":"Expert Opin Biol Ther"},{"key":"787_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15490-y","volume":"15","author":"CR Beudeker","year":"2025","unstructured":"Beudeker CR, van Dalen R, Ruyken M, et al. Antibody dependent complement activation is critical for boosting opsonophagocytosis of Staphylococcus epidermidis in an extremely preterm human whole blood model. Sci Rep. 2025;15:31243. https:\/\/doi.org\/10.1038\/s41598-025-15490-y.","journal-title":"Sci Rep"},{"key":"787_CR103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00281-011-0294-4","volume":"34","author":"JE Cassat","year":"2012","unstructured":"Cassat JE, Skaar EP. Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity. Semin Immunopathol. 2012;34:215\u201335. https:\/\/doi.org\/10.1007\/s00281-011-0294-4.","journal-title":"Semin Immunopathol"},{"key":"787_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.582582","volume":"11","author":"M-T Nguyen","year":"2020","unstructured":"Nguyen M-T, Matsuo M, Niemann S, et al. Lipoproteins in Gram-positive bacteria: abundance, function, fitness. Front Microbiol. 2020;11:582582. https:\/\/doi.org\/10.3389\/fmicb.2020.582582.","journal-title":"Front Microbiol"},{"key":"787_CR105","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1093\/infdis\/jiy635","volume":"219","author":"MR Bennett","year":"2019","unstructured":"Bennett MR, Bombardi RG, Kose N, et al. Human mAbs to Staphylococcus aureus IsdA provide protection through both heme-blocking and Fc-mediated mechanisms. J Infect Dis. 2019;219:1264\u201373. https:\/\/doi.org\/10.1093\/infdis\/jiy635.","journal-title":"J Infect Dis"},{"key":"787_CR106","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1128\/CVI.00085-09","volume":"16","author":"M Brown","year":"2009","unstructured":"Brown M, Kowalski R, Zorman J, et al. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin Vaccine Immunol. 2009;16:1095\u2013104. https:\/\/doi.org\/10.1128\/CVI.00085-09.","journal-title":"Clin Vaccine Immunol"},{"key":"787_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2012.00036","volume":"2","author":"G Pancari","year":"2012","unstructured":"Pancari G, Fan H, Smith S, et al. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Front Cell Infect Microbiol. 2012;2:36. https:\/\/doi.org\/10.3389\/fcimb.2012.00036.","journal-title":"Front Cell Infect Microbiol"},{"key":"787_CR108","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.4161\/hv.34407","volume":"10","author":"TB McNeely","year":"2014","unstructured":"McNeely TB, Shah NA, Fridman A, et al. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors. Hum Vaccin Immunother. 2014;10:3513\u20136. https:\/\/doi.org\/10.4161\/hv.34407.","journal-title":"Hum Vaccin Immunother"},{"key":"787_CR109","unstructured":"Merck Sharp & Dohme LLC. A randomized, multicenter, double-blind, group-sequential study to evaluate the efficacy, immunogenicity, and safety of a single dose of Merck 0657nI Staphylococcus aureus vaccine (V710) in adult patients scheduled for cardiothoracic surgery. 2015. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104927","volume":"299","author":"S Valenciano-Bellido","year":"2023","unstructured":"Valenciano-Bellido S, Caaveiro JMM, Nakakido M, et al. Targeting hemoglobin receptors IsdH and IsdB of Staphylococcus aureus with a single VHH antibody inhibits bacterial growth. J Biol Chem. 2023;299:104927. https:\/\/doi.org\/10.1016\/j.jbc.2023.104927.","journal-title":"J Biol Chem"},{"key":"787_CR111","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jis272","volume":"205","author":"AS Anderson","year":"2012","unstructured":"Anderson AS, Scully IL, Timofeyeva Y, et al. Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis. J Infect Dis. 2012;205:1688\u201396. https:\/\/doi.org\/10.1093\/infdis\/jis272.","journal-title":"J Infect Dis"},{"key":"787_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050579","volume":"11","author":"AR Losito","year":"2022","unstructured":"Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New drugs for the treatment of Pseudomonas aeruginosa infections with limited treatment options: a narrative review. Antibiotics Basel. 2022;11:579. https:\/\/doi.org\/10.3390\/antibiotics11050579.","journal-title":"Antibiotics Basel"},{"key":"787_CR113","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/341069","volume":"186","author":"DW Frank","year":"2002","unstructured":"Frank DW, Vallis A, Wiener-Kronish JP, et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002;186:64\u201373. https:\/\/doi.org\/10.1086\/341069.","journal-title":"J Infect Dis"},{"key":"787_CR114","unstructured":"Pearce T. A randomized, double-blind, placebo-controlled pilot trial of KB001 in mechanically-ventilated patients colonized with Pseudomonas aeruginosa. 2009. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR115","unstructured":"Humanigen, Inc. A Phase I & II randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa. 2014. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR116","unstructured":"MedImmune LLC. A phase 1 randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacokinetics of MEDI3902 in healthy adults. 2017. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR117","unstructured":"MedImmune LLC. A phase 2 proof-of-concept study to evaluate the efficacy and safety of MEDI3902 in mechanically ventilated patients for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa. 2021. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR118","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mib.2008.12.007","volume":"12","author":"J Engel","year":"2009","unstructured":"Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol. 2009;12:61\u20136. https:\/\/doi.org\/10.1016\/j.mib.2008.12.007.","journal-title":"Curr Opin Microbiol"},{"key":"787_CR119","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrmicro.2017.20","volume":"15","author":"W Deng","year":"2017","unstructured":"Deng W, Marshall NC, Rowland JL, et al. Assembly, structure, function and regulation of type III secretion systems. Nat Rev Microbiol. 2017;15:323\u201337. https:\/\/doi.org\/10.1038\/nrmicro.2017.20.","journal-title":"Nat Rev Microbiol"},{"key":"787_CR120","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1111\/1462-2920.13755","volume":"19","author":"Y Hu","year":"2017","unstructured":"Hu Y, Huang H, Cheng X, et al. A global survey of bacterial type III secretion systems and their effectors. Environ Microbiol. 2017;19:3879\u201395. https:\/\/doi.org\/10.1111\/1462-2920.13755.","journal-title":"Environ Microbiol"},{"key":"787_CR121","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00405-25","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Guo S, Jiang L, et al. Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV. Antimicrob Agents Chemother. 2025. https:\/\/doi.org\/10.1128\/aac.00405-25.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR122","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.4161\/21645515.2014.971641","volume":"10","author":"T Sawa","year":"2014","unstructured":"Sawa T, Ito E, Nguyen VH, Haight M. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Hum Vaccin Immunother. 2014;10:2843\u201352. https:\/\/doi.org\/10.4161\/21645515.2014.971641.","journal-title":"Hum Vaccin Immunother"},{"key":"787_CR123","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jcf.2017.12.006","volume":"17","author":"R Jain","year":"2018","unstructured":"Jain R, Beckett VV, Konstan MW, et al. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018;17:484\u201391. https:\/\/doi.org\/10.1016\/j.jcf.2017.12.006.","journal-title":"J Cyst Fibros"},{"key":"787_CR124","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00694-24","author":"S Numata","year":"2024","unstructured":"Numata S, Hara T, Izawa M, et al. Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal Pseudomonas aeruginosa infection via inhibition of toxin translocation by the type III secretion system. Antimicrob Agents Chemother. 2024. https:\/\/doi.org\/10.1128\/aac.00694-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR125","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1016\/j.cell.2023.10.002","volume":"186","author":"A Simonis","year":"2023","unstructured":"Simonis A, Kreer C, Albus A, et al. Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa. Cell. 2023;186:5098-113.e19. https:\/\/doi.org\/10.1016\/j.cell.2023.10.002.","journal-title":"Cell"},{"key":"787_CR126","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.105195.2","author":"J-M Desveaux","year":"2025","unstructured":"Desveaux J-M, Faudry E, Contreras-Martel C, et al. Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of Pseudomonas aeruginosa act through distinct mechanisms. Elife. 2025. https:\/\/doi.org\/10.7554\/eLife.105195.2.","journal-title":"Elife"},{"key":"787_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2024.103440","volume":"5","author":"A Albus","year":"2024","unstructured":"Albus A, Kreer C, Klein F, et al. Protocol for developing Pseudomonas aeruginosa type III secretion system-neutralizing monoclonal antibodies from human B cells. STAR Protoc. 2024;5:103440. https:\/\/doi.org\/10.1016\/j.xpro.2024.103440.","journal-title":"STAR Protoc"},{"key":"787_CR128","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20120033","volume":"209","author":"A DiGiandomenico","year":"2012","unstructured":"DiGiandomenico A, Warrener P, Hamilton M, et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J Exp Med. 2012;209:1273\u201387. https:\/\/doi.org\/10.1084\/jem.20120033.","journal-title":"J Exp Med"},{"key":"787_CR129","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009655","volume":"6","author":"A DiGiandomenico","year":"2014","unstructured":"DiGiandomenico A, Keller AE, Gao C, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6:262ra155. https:\/\/doi.org\/10.1126\/scitranslmed.3009655.","journal-title":"Sci Transl Med"},{"key":"787_CR130","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1093\/infdis\/jiy438","volume":"218","author":"DE Tabor","year":"2018","unstructured":"Tabor DE, Oganesyan V, Keller AE, et al. Pseudomonas aeruginosa PcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates. J Infect Dis. 2018;218:1983\u201394. https:\/\/doi.org\/10.1093\/infdis\/jiy438.","journal-title":"J Infect Dis"},{"key":"787_CR131","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1164\/rccm.202308-1403OC","volume":"210","author":"MB Long","year":"2024","unstructured":"Long MB, Gilmour A, Kehl M, et al. A bispecific monoclonal antibody targeting Psl and PcrV enhances neutrophil-mediated killing of Pseudomonas aeruginosa in patients with bronchiectasis. Am J Respir Crit Care Med. 2024;210:35\u201346. https:\/\/doi.org\/10.1164\/rccm.202308-1403OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"787_CR132","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1172\/JCI89652","volume":"127","author":"A Thanabalasuriar","year":"2017","unstructured":"Thanabalasuriar A, Surewaard BGJ, Willson ME, et al. Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature. J Clin Invest. 2017;127:2249\u201361. https:\/\/doi.org\/10.1172\/JCI89652.","journal-title":"J Clin Invest"},{"key":"787_CR133","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02565-17","volume":"62","author":"HN Le","year":"2018","unstructured":"Le HN, Quetz JS, Tran VG, et al. MEDI3902 correlates of protection against severe Pseudomonas aeruginosa pneumonia in a rabbit acute pneumonia model. Antimicrob Agents Chemother. 2018;62:10.1128\/aac.02565-17. https:\/\/doi.org\/10.1128\/aac.02565-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR134","doi-asserted-by":"publisher","first-page":"e00710","DOI":"10.1128\/AAC.00710-19","volume":"63","author":"HN Le","year":"2019","unstructured":"Le HN, Tran VG, Vu TTT, et al. Treatment efficacy of MEDI3902 in Pseudomonas aeruginosa bloodstream infection and acute pneumonia rabbit models. Antimicrob Agents Chemother. 2019;63:e00710-e719. https:\/\/doi.org\/10.1128\/AAC.00710-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR135","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.chom.2019.02.007","volume":"25","author":"A Thanabalasuriar","year":"2019","unstructured":"Thanabalasuriar A, Scott BNV, Peiseler M, et al. Neutrophil extracellular traps confine Pseudomonas aeruginosa ocular biofilms and restrict brain invasion. Cell Host Microbe. 2019;25:526-36.e4. https:\/\/doi.org\/10.1016\/j.chom.2019.02.007.","journal-title":"Cell Host Microbe"},{"key":"787_CR136","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02022-21","volume":"66","author":"F Aguiar-Alves","year":"2022","unstructured":"Aguiar-Alves F, Le HN, Tran VG, et al. Antivirulence bispecific monoclonal antibody-mediated protection against Pseudomonas aeruginosa ventilator-associated pneumonia in a rabbit model. Antimicrob Agents Chemother. 2022;66:e0202221. https:\/\/doi.org\/10.1128\/AAC.02022-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1297281","author":"E Gras","year":"2023","unstructured":"Gras E, Vu TTT, Nguyen NTQ, et al. Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development. Front Cell Infect Microbiol. 2023. https:\/\/doi.org\/10.3389\/fcimb.2023.1297281.","journal-title":"Front Cell Infect Microbiol"},{"key":"787_CR138","doi-asserted-by":"publisher","first-page":"629.e1","DOI":"10.1016\/j.cmi.2018.08.004","volume":"25","author":"SO Ali","year":"2019","unstructured":"Ali SO, Yu XQ, Robbie GJ, et al. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. 2019;25:629.e1-6. https:\/\/doi.org\/10.1016\/j.cmi.2018.08.004.","journal-title":"Clin Microbiol Infect"},{"key":"787_CR139","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04204-9","volume":"26","author":"J Chastre","year":"2022","unstructured":"Chastre J, Fran\u00e7ois B, Bourgeois M, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022;26:355. https:\/\/doi.org\/10.1186\/s13054-022-04204-9.","journal-title":"Crit Care"},{"key":"787_CR140","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2017","author":"D Ara\u00fajo","year":"2018","unstructured":"Ara\u00fajo D, Shteinberg M, Aliberti S, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.01953-2017.","journal-title":"Eur Respir J"},{"key":"787_CR141","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A3117","volume":"211","author":"M Long","year":"2025","unstructured":"Long M, Hull R, Gilmour A, et al. A bispecific monoclonal antibody targeting Psl and PcrV for chronic Pseudomonas aeruginosa infection in patients with bronchiectasis: results from a randomized, double-blind placebo-controlled trial (GREAT-2). Am J Respir Crit Care Med. 2025;211:A3117. https:\/\/doi.org\/10.1164\/ajrccm.2025.211.Abstracts.A3117.","journal-title":"Am J Respir Crit Care Med"},{"key":"787_CR142","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000515740","volume":"13","author":"RS Gabarin","year":"2021","unstructured":"Gabarin RS, Li M, Zimmel PA, et al. Intracellular and extracellular lipopolysaccharide signaling in sepsis: avenues for novel therapeutic strategies. J Innate Immun. 2021;13:323\u201332. https:\/\/doi.org\/10.1159\/000515740.","journal-title":"J Innate Immun"},{"key":"787_CR143","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/jac\/dkr038","volume":"66","author":"T Secher","year":"2011","unstructured":"Secher T, Fauconnier L, Szade A, et al. Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection. J Antimicrob Chemother. 2011;66:1100\u20139. https:\/\/doi.org\/10.1093\/jac\/dkr038.","journal-title":"J Antimicrob Chemother"},{"key":"787_CR144","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01699-08","volume":"53","author":"H Lazar","year":"2009","unstructured":"Lazar H, Horn MP, Zuercher AW, et al. Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob Agents Chemother. 2009;53:34426. https:\/\/doi.org\/10.1128\/AAC.01699-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR145","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s10096-014-2156-1","volume":"33","author":"Y-A Que","year":"2014","unstructured":"Que Y-A, Lazar H, Wolff M, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis. 2014;33:1861\u20137. https:\/\/doi.org\/10.1007\/s10096-014-2156-1.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"787_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1191806","volume":"13","author":"J Kang","year":"2023","unstructured":"Kang J, Mateu-Borr\u00e1s M, Monroe HL, et al. Monoclonal antibodies against lipopolysaccharide protect against Pseudomonas aeruginosa challenge in mice. Front Cell Infect Microbiol. 2023;13:1191806. https:\/\/doi.org\/10.3389\/fcimb.2023.1191806.","journal-title":"Front Cell Infect Microbiol"},{"key":"787_CR147","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fmicb.2011.00118","volume":"2","author":"JS Lam","year":"2011","unstructured":"Lam JS, Taylor VL, Islam ST, et al. Genetic and functional diversity of Pseudomonas aeruginosa lipopolysaccharide. Front Microbiol. 2011;2:118. https:\/\/doi.org\/10.3389\/fmicb.2011.00118.","journal-title":"Front Microbiol"},{"key":"787_CR148","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/BF01569821","volume":"15","author":"A Boyd","year":"1995","unstructured":"Boyd A, Chakrabarty AM. Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. J Ind Microbiol. 1995;15:162\u20138. https:\/\/doi.org\/10.1007\/BF01569821.","journal-title":"J Ind Microbiol"},{"key":"787_CR149","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.1093\/ofid\/ofz360.742","volume":"6","author":"A Loos","year":"2019","unstructured":"Loos A, Weich N, Woo J, et al. 674. Pre-clinical and phase I safety data for anti-Pseudomonas aeruginosa human monoclonal antibody AR-105. Open Forum Infect Dis. 2019;6:S307\u20138. https:\/\/doi.org\/10.1093\/ofid\/ofz360.742.","journal-title":"Open Forum Infect Dis"},{"key":"787_CR150","unstructured":"Aridis Pharmaceuticals, Inc. Placebo-controlled, double-blind, randomized study of Aerucin\u00ae as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia. 2022. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR151","unstructured":"Aridis Pharmaceuticals, Inc. A randomized double-blind placebo-controlled multicenter phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of ventilator-associated pneumonia (VAP) caused by S. aureus. 2023. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.105060","volume":"158","author":"A Zahedi Bialvaei","year":"2021","unstructured":"Zahedi Bialvaei A, Razavi S, Notash Haghighat F, et al. Monoclonal antibody directed to the PilQ -PilA DSL region in Pseudomonas aeruginosa improves survival of infected mice with antibiotic combination. Microb Pathog. 2021;158:105060. https:\/\/doi.org\/10.1016\/j.micpath.2021.105060.","journal-title":"Microb Pathog"},{"key":"787_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1117844","author":"AM Horspool","year":"2023","unstructured":"Horspool AM, Sen-Kilic E, Malkowski AC, et al. Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244. Front Cell Infect Microbiol. 2023. https:\/\/doi.org\/10.3389\/fcimb.2023.1117844.","journal-title":"Front Cell Infect Microbiol"},{"key":"787_CR154","doi-asserted-by":"publisher","first-page":"e00330","DOI":"10.1128\/iai.00330-24","volume":"93","author":"M Mateu-Borr\u00e1s","year":"2024","unstructured":"Mateu-Borr\u00e1s M, Dublin SR, Kang J, et al. Novel broadly reactive monoclonal antibody protects against Pseudomonas aeruginosa infection. Infect Immun. 2024;93:e00330-e424. https:\/\/doi.org\/10.1128\/iai.00330-24.","journal-title":"Infect Immun"},{"key":"787_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110380","volume":"26","author":"G Lacroix","year":"2025","unstructured":"Lacroix G, Lenormand J-L. EPY001, a novel monoclonal antibody against Pseudomonas aeruginosa targeting OprF. Int J Mol Sci. 2025;26:10380. https:\/\/doi.org\/10.3390\/ijms262110380.","journal-title":"Int J Mol Sci"},{"key":"787_CR156","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1517\/14656561003596350","volume":"11","author":"A Michalopoulos","year":"2010","unstructured":"Michalopoulos A, Falagas ME. Treatment of Acinetobacter infections. Expert Opin Pharmacother. 2010;11:779\u201388. https:\/\/doi.org\/10.1517\/14656561003596350.","journal-title":"Expert Opin Pharmacother"},{"key":"787_CR157","unstructured":"CDC. Antibiotic resistance threats in the United States, 2013. https:\/\/stacks.cdc.gov. Accessed 11 Sept 2025."},{"key":"787_CR158","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1093\/cid\/ciad109","volume":"76","author":"M Castanheira","year":"2023","unstructured":"Castanheira M, Mendes RE, Gales AC. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex. Clin Infect Dis. 2023;76:S166\u201378. https:\/\/doi.org\/10.1093\/cid\/ciad109.","journal-title":"Clin Infect Dis"},{"key":"787_CR159","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1128\/CMR.00058-16","volume":"30","author":"D Wong","year":"2017","unstructured":"Wong D, Nielsen TB, Bonomo RA, et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30:409\u201347. https:\/\/doi.org\/10.1128\/CMR.00058-16.","journal-title":"Clin Microbiol Rev"},{"key":"787_CR160","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1128\/AAC.02101-13","volume":"58","author":"Y Smani","year":"2014","unstructured":"Smani Y, F\u00e0brega A, Roca I, et al. Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii. Antimicrob Agents Chemother. 2014;58:1806\u20138. https:\/\/doi.org\/10.1128\/AAC.02101-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-023-02904-y","volume":"23","author":"BL Schmitt","year":"2023","unstructured":"Schmitt BL, Leal BF, Leyser M, et al. Increased ompW and ompA expression and higher virulence of Acinetobacter baumannii persister cells. BMC Microbiol. 2023;23:157. https:\/\/doi.org\/10.1186\/s12866-023-02904-y.","journal-title":"BMC Microbiol"},{"key":"787_CR162","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029446","volume":"7","author":"G Luo","year":"2012","unstructured":"Luo G, Lin L, Ibrahim AS, et al. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS ONE. 2012;7:e29446. https:\/\/doi.org\/10.1371\/journal.pone.0029446.","journal-title":"PLoS ONE"},{"key":"787_CR163","doi-asserted-by":"publisher","first-page":"e00591","DOI":"10.1128\/IAI.00591-17","volume":"85","author":"SX Wang-Lin","year":"2017","unstructured":"Wang-Lin SX, Olson R, Beanan JM, et al. The capsular polysaccharide of Acinetobacter baumannii is an obstacle for therapeutic passive immunization strategies. Infect Immun. 2017;85:e00591-e617. https:\/\/doi.org\/10.1128\/IAI.00591-17.","journal-title":"Infect Immun"},{"issue":"5","key":"787_CR164","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1128\/iai.68.5.2402-2409.2000","volume":"68","author":"TK Held","year":"2000","unstructured":"Held TK, Jendrike NRM, Rukavina T, et al. Binding to and opsonophagocytic activity of O-antigen-specific monoclonal antibodies against encapsulated and nonencapsulated Klebsiella pneumoniae serotype O1 strains. Infect Immun. 2000;68(5):2402\u20139. https:\/\/doi.org\/10.1128\/iai.68.5.2402-2409.2000.","journal-title":"Infect Immun"},{"key":"787_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009291","volume":"17","author":"Y Talyansky","year":"2021","unstructured":"Talyansky Y, Nielsen TB, Yan J, et al. Capsule carbohydrate structure determines virulence in Acinetobacter baumannii. PLoS Pathog. 2021;17:e1009291. https:\/\/doi.org\/10.1371\/journal.ppat.1009291.","journal-title":"PLoS Pathog"},{"key":"787_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2021.113169","volume":"499","author":"O Yeganeh","year":"2021","unstructured":"Yeganeh O, Shabani M, Pakzad P, et al. Production and characterization of novel monoclonal antibodies against outer membrane protein A (OmpA) of Acinetobacter baumannii. J Immunol Methods. 2021;499:113169. https:\/\/doi.org\/10.1016\/j.jim.2021.113169.","journal-title":"J Immunol Methods"},{"key":"787_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-022-00523-5","volume":"21","author":"O Yeganeh","year":"2022","unstructured":"Yeganeh O, Shabani M, Pakzad P, et al. Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with drug resistant pulsotypes of Acinetobacter baumannii as a potential therapeutic approach. Ann Clin Microbiol Antimicrob. 2022;21:30. https:\/\/doi.org\/10.1186\/s12941-022-00523-5.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"787_CR168","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2437243","volume":"14","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Cheng H, Yu P, et al. High-throughput single-cell analysis reveals Omp38-specific monoclonal antibodies that protect against Acinetobacter baumannii infection. Emerg Microbes Infect. 2025;14:2437243. https:\/\/doi.org\/10.1080\/22221751.2024.2437243.","journal-title":"Emerg Microbes Infect"},{"key":"787_CR169","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000878","volume":"8","author":"SM Cahill","year":"2022","unstructured":"Cahill SM, Hall RM, Kenyon JJ. An update to the database for Acinetobacter baumannii capsular polysaccharide locus typing extends the extensive and diverse repertoire of genes found at and outside the K locus. Microb Genom. 2022;8:mgen000878. https:\/\/doi.org\/10.1099\/mgen.0.000878.","journal-title":"Microb Genom"},{"key":"787_CR170","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1128\/IAI.01184-12","volume":"81","author":"TA Russo","year":"2013","unstructured":"Russo TA, Beanan JM, Olson R, et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013;81:915\u201322. https:\/\/doi.org\/10.1128\/IAI.01184-12.","journal-title":"Infect Immun"},{"key":"787_CR171","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1124\/jpet.118.253617","volume":"368","author":"SX Wang-Lin","year":"2019","unstructured":"Wang-Lin SX, Olson R, Beanan JM, et al. Antibody dependent enhancement of Acinetobacter baumannii infection in a mouse pneumonia model. J Pharmacol Exp Ther. 2019;368:475\u201389. https:\/\/doi.org\/10.1124\/jpet.118.253617.","journal-title":"J Pharmacol Exp Ther"},{"key":"787_CR172","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/infdis\/jix315","volume":"216","author":"TB Nielsen","year":"2017","unstructured":"Nielsen TB, Pantapalangkoor P, Luna BM, et al. Monoclonal antibody protects against Acinetobacter baumannii infection by enhancing bacterial clearance and evading sepsis. J Infect Dis. 2017;216:489\u2013501. https:\/\/doi.org\/10.1093\/infdis\/jix315.","journal-title":"J Infect Dis"},{"key":"787_CR173","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab265","author":"TB Nielsen","year":"2021","unstructured":"Nielsen TB, Yan J, Luna BM, et al. Monoclonal antibody requires immunomodulation for efficacy against Acinetobacter baumannii infection. J Infect Dis. 2021. https:\/\/doi.org\/10.1093\/infdis\/jiab265.","journal-title":"J Infect Dis"},{"key":"787_CR174","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00162-21","volume":"89","author":"TB Nielsen","year":"2021","unstructured":"Nielsen TB, Yan J, Slarve M, et al. Monoclonal antibody therapy against Acinetobacter baumannii. Infect Immun. 2021;89:e0016221. https:\/\/doi.org\/10.1128\/IAI.00162-21.","journal-title":"Infect Immun"},{"key":"787_CR175","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174799","author":"MJ Slarve","year":"2024","unstructured":"Slarve MJ, Bowler N, Burk E, et al. Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.174799.","journal-title":"JCI Insight"},{"key":"787_CR176","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/infdis\/jiac499","volume":"227","author":"TB Nielsen","year":"2023","unstructured":"Nielsen TB, Yan J, Slarve M, et al. Development of a bispecific antibody targeting clinical isolates of Acinetobacter baumannii. J Infect Dis. 2023;227:1042\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiac499.","journal-title":"J Infect Dis"},{"key":"787_CR177","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00086-23","volume":"67","author":"M Slarve","year":"2023","unstructured":"Slarve M, Reyna Z, Burk E, et al. Therapeutic, humanized monoclonal antibody exhibits broad binding and protective efficacy against Acinetobacter baumannii. Antimicrob Agents Chemother. 2023;67:e0008623. https:\/\/doi.org\/10.1128\/aac.00086-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR178","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0340857","volume":"21","author":"M Slarve","year":"2026","unstructured":"Slarve M, Jaramillo H, Luna B, Spellberg B. A monoclonal antibody raised against Acinetobacter baumannii capsular carbohydrate exhibits cross-species in vitro binding against Pseudomonas aeruginosa. PLoS ONE. 2026;21:e0340857. https:\/\/doi.org\/10.1371\/journal.pone.0340857.","journal-title":"PLoS ONE"},{"key":"787_CR179","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04141-22","volume":"11","author":"A Karatovskaya","year":"2023","unstructured":"Karatovskaya A, Rudenko N, Zamyatina A, et al. Protective capacity of monoclonal antibodies against Acinetobacter baumannii K9 capsular polysaccharide. Microbiol Spectr. 2023;11:e0414122. https:\/\/doi.org\/10.1128\/spectrum.04141-22.","journal-title":"Microbiol Spectr"},{"key":"787_CR180","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1021\/acscentsci.3c01507","volume":"10","author":"X Yang","year":"2024","unstructured":"Yang X, Wei R, Liu H, et al. Discovery of a monoclonal antibody that targets cell-surface pseudaminic acid of Acinetobacter baumannii with direct bactericidal effect. ACS Cent Sci. 2024;10:439\u201346. https:\/\/doi.org\/10.1021\/acscentsci.3c01507.","journal-title":"ACS Cent Sci"},{"key":"787_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52357-8","volume":"15","author":"S Baker","year":"2024","unstructured":"Baker S, Krishna A, Higham S, et al. Exploiting human immune repertoire transgenic mice for protective monoclonal antibodies against antimicrobial resistant Acinetobacter baumannii. Nat Commun. 2024;15:7979. https:\/\/doi.org\/10.1038\/s41467-024-52357-8.","journal-title":"Nat Commun"},{"key":"787_CR182","doi-asserted-by":"publisher","DOI":"10.3390\/biology13020078","volume":"13","author":"R Abbas","year":"2024","unstructured":"Abbas R, Chakkour M, Zein El Dine H, et al. General overview of Klebsiella pneumonia: epidemiology and the role of siderophores in its pathogenicity. Biology. 2024;13:78. https:\/\/doi.org\/10.3390\/biology13020078.","journal-title":"Biology"},{"key":"787_CR183","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s10096-011-1396-6","volume":"31","author":"DK Pomakova","year":"2012","unstructured":"Pomakova DK, Hsiao C-B, Beanan JM, et al. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant. Eur J Clin Microbiol Infect Dis. 2012;31:981\u20139. https:\/\/doi.org\/10.1007\/s10096-011-1396-6.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"787_CR184","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.14202\/vetworld.2022.2172-2179","volume":"15","author":"KHP Riwu","year":"2022","unstructured":"Riwu KHP, Effendi MH, Rantam FA, et al. A review: virulence factors of Klebsiella pneumonia as emerging infection on the food chain. Vet World. 2022;15:2172\u20139. https:\/\/doi.org\/10.14202\/vetworld.2022.2172-2179.","journal-title":"Vet World"},{"key":"787_CR185","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000073","volume":"2","author":"R Follador","year":"2016","unstructured":"Follador R, Heinz E, Wyres KL, et al. The diversity of Klebsiella pneumoniae surface polysaccharides. Microb Genom. 2016;2:e000073. https:\/\/doi.org\/10.1099\/mgen.0.000073.","journal-title":"Microb Genom"},{"key":"787_CR186","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1128\/iai.58.5.1421-1428.1990","volume":"58","author":"Y Meno","year":"1990","unstructured":"Meno Y, Amako K. Morphological evidence for penetration of anti-O antibody through the capsule of Klebsiella pneumoniae. Infect Immun. 1990;58:1421\u20138. https:\/\/doi.org\/10.1128\/iai.58.5.1421-1428.1990.","journal-title":"Infect Immun"},{"key":"787_CR187","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1128\/iai.62.4.1282-1288.1994","volume":"62","author":"M Trautmann","year":"1994","unstructured":"Trautmann M, Vogt K, Hammack C, Cross AS. A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides. Infect Immun. 1994;62:1282\u20138. https:\/\/doi.org\/10.1128\/iai.62.4.1282-1288.1994.","journal-title":"Infect Immun"},{"key":"787_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09391-3","author":"E Roscioli","year":"2025","unstructured":"Roscioli E, Zucconi Galli Fonseca V, Bosch SS, et al. Monoclonal antibodies protect against pandrug-resistant Klebsiella pneumoniae. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-025-09391-3.","journal-title":"Nature"},{"key":"787_CR189","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/21505594.2017.1279778","volume":"8","author":"V Szij\u00e1rt\u00f3","year":"2017","unstructured":"Szij\u00e1rt\u00f3 V, Guachalla LM, Hartl K, et al. Endotoxin neutralization by an O-antigen specific monoclonal antibody: a potential novel therapeutic approach against Klebsiella pneumoniae ST258. Virulence. 2017;8:1203\u201315. https:\/\/doi.org\/10.1080\/21505594.2017.1279778.","journal-title":"Virulence"},{"key":"787_CR190","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06682-2","volume":"7","author":"LM Guachalla","year":"2017","unstructured":"Guachalla LM, Stojkovic K, Hartl K. Discovery of monoclonal antibodies cross-reactive to novel subserotypes of K. pneumoniae O3. Sci Rep. 2017;7:6635. https:\/\/doi.org\/10.1038\/s41598-017-06682-2.","journal-title":"Sci Rep"},{"key":"787_CR191","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92774","volume":"2","author":"TS Cohen","year":"2017","unstructured":"Cohen TS, Pelletier M, Cheng L, et al. Anti-LPS antibodies protect against Klebsiella pneumoniae by empowering neutrophil-mediated clearance without neutralizing TLR4. JCI Insight. 2017;2:e92774. https:\/\/doi.org\/10.1172\/jci.insight.92774.","journal-title":"JCI Insight"},{"key":"787_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02223-7","volume":"8","author":"ME Pennini","year":"2017","unstructured":"Pennini ME, De Marco A, Pelletier M, et al. Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae. Nat Commun. 2017;8:1991. https:\/\/doi.org\/10.1038\/s41467-017-02223-7.","journal-title":"Nat Commun"},{"key":"787_CR193","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.2006123","volume":"14","author":"SK Berry","year":"2022","unstructured":"Berry SK, Rust S, Caceres C, et al. Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae. MAbs. 2022;14:2006123. https:\/\/doi.org\/10.1080\/19420862.2021.2006123.","journal-title":"MAbs"},{"key":"787_CR194","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/infdis\/jiw021","volume":"213","author":"Q Wang","year":"2016","unstructured":"Wang Q, Chang C-S, Pennini M, et al. Target-agnostic identification of functional monoclonal antibodies against Klebsiella pneumoniae multimeric MrkA fimbrial subunit. J Infect Dis. 2016;213:1800\u20138. https:\/\/doi.org\/10.1093\/infdis\/jiw021.","journal-title":"J Infect Dis"},{"key":"787_CR195","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170529","volume":"12","author":"Q Wang","year":"2017","unstructured":"Wang Q, Chen Y, Cvitkovic R, et al. Anti-MrkA monoclonal antibodies reveal distinct structural and antigenic features of MrkA. PLoS ONE. 2017;12:e0170529. https:\/\/doi.org\/10.1371\/journal.pone.0170529.","journal-title":"PLoS ONE"},{"key":"787_CR196","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00400-24","volume":"12","author":"SK Berry","year":"2024","unstructured":"Berry SK, Rust S, Irving L, et al. Characterization of mAbs against Klebsiella pneumoniae type 3 fimbriae isolated in a target-independent phage display campaign. Microbiol Spectr. 2024;12:e00400-24. https:\/\/doi.org\/10.1128\/spectrum.00400-24.","journal-title":"Microbiol Spectr"},{"key":"787_CR197","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw0698","volume":"11","author":"EDB Lopatto","year":"2025","unstructured":"Lopatto EDB, Santiago-Borges JM, Sanick DA, et al. Monoclonal antibodies targeting the FimH adhesin protect against uropathogenic E. coli UTI. Sci Adv. 2025;11:eadw0698. https:\/\/doi.org\/10.1126\/sciadv.adw0698.","journal-title":"Sci Adv"},{"key":"787_CR198","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00456-16","volume":"24","author":"E Diago-Navarro","year":"2017","unstructured":"Diago-Navarro E, Calatayud-Baselga I, Sun D, et al. Antibody-based immunotherapy to treat and prevent infection with hypervirulent Klebsiella pneumoniae. Clin Vaccine Immunol. 2017;24:e00456-16. https:\/\/doi.org\/10.1128\/CVI.00456-16.","journal-title":"Clin Vaccine Immunol"},{"key":"787_CR199","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1073\/pnas.1321364111","volume":"111","author":"FR DeLeo","year":"2014","unstructured":"DeLeo FR, Chen L, Porcella SF, et al. Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci USA. 2014;111:4988\u201393. https:\/\/doi.org\/10.1073\/pnas.1321364111.","journal-title":"Proc Natl Acad Sci USA"},{"key":"787_CR200","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00091-18","volume":"9","author":"E Diago-Navarro","year":"2018","unstructured":"Diago-Navarro E, Motley MP, Ruiz-Per\u00e9z G, et al. Novel, broadly reactive anticapsular antibodies against carbapenem-resistant Klebsiella pneumoniae protect from infection. MBio. 2018;9:10.1128\/mbio.00091-18. https:\/\/doi.org\/10.1128\/mbio.00091-18.","journal-title":"MBio"},{"key":"787_CR201","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01760-22","volume":"10","author":"K Banerjee","year":"2022","unstructured":"Banerjee K, Motley MP, Boniche-Alfaro C, et al. Patient-derived antibody data yields development of broadly cross-protective monoclonal antibody against ST258 carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr. 2022;10:e01760-22. https:\/\/doi.org\/10.1128\/spectrum.01760-22.","journal-title":"Microbiol Spectr"},{"key":"787_CR202","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000800","volume":"8","author":"MMC Lam","year":"2022","unstructured":"Lam MMC, Wick RR, Judd LM, et al. Kaptive 2.0: updated capsule and lipopolysaccharide locus typing for the Klebsiella pneumoniae species complex. Microb Genom. 2022;8:000800. https:\/\/doi.org\/10.1099\/mgen.0.000800.","journal-title":"Microb Genom"},{"key":"787_CR203","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.cmi.2023.10.023","volume":"30","author":"A Vasiliu","year":"2024","unstructured":"Vasiliu A, Martinez L, Gupta RK, et al. Tuberculosis prevention: current strategies and future directions. Clin Microbiol Infect. 2024;30:1123\u201330. https:\/\/doi.org\/10.1016\/j.cmi.2023.10.023.","journal-title":"Clin Microbiol Infect"},{"key":"787_CR204","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cmi.2023.07.013","volume":"30","author":"I Motta","year":"2024","unstructured":"Motta I, Boeree M, Chesov D, et al. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect. 2024;30:1107\u201314. https:\/\/doi.org\/10.1016\/j.cmi.2023.07.013.","journal-title":"Clin Microbiol Infect"},{"key":"787_CR205","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41579-025-01201-x","volume":"23","author":"DF Warner","year":"2025","unstructured":"Warner DF, Barczak AK, Gutierrez MG, Mizrahi V. Mycobacterium tuberculosis biology, pathogenicity and interaction with the host. Nat Rev Microbiol. 2025;23:788\u2013804. https:\/\/doi.org\/10.1038\/s41579-025-01201-x.","journal-title":"Nat Rev Microbiol"},{"key":"787_CR206","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00996","author":"JY Kawahara","year":"2019","unstructured":"Kawahara JY, Irvine EB, Alter G. A case for antibodies as mechanistic correlates of immunity in tuberculosis. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.00996.","journal-title":"Front Immunol"},{"key":"787_CR207","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006250","volume":"13","author":"R Prados-Rosales","year":"2017","unstructured":"Prados-Rosales R, Carre\u00f1o L, Cheng T, et al. Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine. PLoS Pathog. 2017;13:e1006250. https:\/\/doi.org\/10.1371\/journal.ppat.1006250.","journal-title":"PLoS Pathog"},{"key":"787_CR208","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2:695\u2013703. https:\/\/doi.org\/10.1038\/nrmicro974.","journal-title":"Nat Rev Microbiol"},{"key":"787_CR209","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","volume":"167","author":"LL Lu","year":"2016","unstructured":"Lu LL, Chung AW, Rosebrock TR, et al. A functional role for antibodies in tuberculosis. Cell. 2016;167:433-3.e14. https:\/\/doi.org\/10.1016\/j.cell.2016.08.072.","journal-title":"Cell"},{"key":"787_CR210","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","volume":"577","author":"PA Darrah","year":"2020","unstructured":"Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature. 2020;577:95\u2013102. https:\/\/doi.org\/10.1038\/s41586-019-1817-8.","journal-title":"Nature"},{"key":"787_CR211","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41590-021-01066-1","volume":"22","author":"EB Irvine","year":"2021","unstructured":"Irvine EB, O\u2019Neil A, Darrah PA, et al. Robust IgM responses following intravenous vaccination with Bacille Calmette\u2013Gu\u00e9rin associate with prevention of Mycobacterium tuberculosis infection in macaques. Nat Immunol. 2021;22:1515\u201323. https:\/\/doi.org\/10.1038\/s41590-021-01066-1.","journal-title":"Nat Immunol"},{"key":"787_CR212","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.1073\/pnas.162246899","volume":"99","author":"K Pethe","year":"2002","unstructured":"Pethe K, Bifani P, Drobecq H, et al. Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci. 2002;99:10759\u201364. https:\/\/doi.org\/10.1073\/pnas.162246899.","journal-title":"Proc Natl Acad Sci"},{"key":"787_CR213","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.tube.2006.01.016","volume":"86","author":"C Locht","year":"2006","unstructured":"Locht C, Hougardy J-M, Rouanet C, et al. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis. 2006;86:303\u20139. https:\/\/doi.org\/10.1016\/j.tube.2006.01.016.","journal-title":"Tuberculosis"},{"key":"787_CR214","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/35084083","volume":"412","author":"K Pethe","year":"2001","unstructured":"Pethe K, Alonso S, Biet F, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature. 2001;412:190\u20134. https:\/\/doi.org\/10.1038\/35084083.","journal-title":"Nature"},{"key":"787_CR215","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-2567.2004.01809.x","volume":"111","author":"A Williams","year":"2004","unstructured":"Williams A, Reljic R, Naylor I, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. 2004;111:328\u201333. https:\/\/doi.org\/10.1111\/j.1365-2567.2004.01809.x.","journal-title":"Immunology"},{"key":"787_CR216","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2249.2004.02593.x","volume":"138","author":"B Hamasur","year":"2004","unstructured":"Hamasur B, Haile M, Pawlowski A, et al. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab\u2019) fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol. 2004;138:30\u20138. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02593.x.","journal-title":"Clin Exp Immunol"},{"key":"787_CR217","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018432","volume":"5","author":"JM Achkar","year":"2015","unstructured":"Achkar JM, Chan J, Casadevall A. Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis. Cold Spring Harb Perspect Med. 2015;5:a018432. https:\/\/doi.org\/10.1101\/cshperspect.a018432.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"787_CR218","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1172\/JCI128459","volume":"130","author":"T Chen","year":"2020","unstructured":"Chen T, Blanc C, Liu Y, et al. Capsular glycan recognition provides antibody-mediated immunity against tuberculosis. J Clin Investig. 2020;130:1808\u201322. https:\/\/doi.org\/10.1172\/JCI128459.","journal-title":"J Clin Investig"},{"key":"787_CR219","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.immuni.2025.05.004","volume":"58","author":"PS Grace","year":"2025","unstructured":"Grace PS, Peters JM, Sixsmith J, et al. Antibody-Fab and -Fc features promote Mycobacterium tuberculosis restriction. Immunity. 2025;58:1586-97.e5. https:\/\/doi.org\/10.1016\/j.immuni.2025.05.004.","journal-title":"Immunity"},{"key":"787_CR220","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20930-0","volume":"12","author":"A Watson","year":"2021","unstructured":"Watson A, Li H, Ma B, et al. Human antibodies targeting a Mycobacterium transporter protein mediate protection against tuberculosis. Nat Commun. 2021;12:602. https:\/\/doi.org\/10.1038\/s41467-021-20930-0.","journal-title":"Nat Commun"},{"key":"787_CR221","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1038\/s41564-024-01777-9","volume":"9","author":"EB Irvine","year":"2024","unstructured":"Irvine EB, Nikolov A, Khan MZ, et al. Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis. Nat Microbiol. 2024;9:2369\u201382. https:\/\/doi.org\/10.1038\/s41564-024-01777-9.","journal-title":"Nat Microbiol"},{"key":"787_CR222","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.18.665318","author":"R Bouzeyen","year":"2025","unstructured":"Bouzeyen R, Sithole N, Watson A, et al. Early antibody-mediated immunity to tuberculosis in mice requires NLRP3. BioRxiv Prepr Serv Biol. 2025. https:\/\/doi.org\/10.1101\/2025.07.18.665318.","journal-title":"BioRxiv Prepr Serv Biol."},{"key":"787_CR223","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1542\/peds.112.3.514","volume":"112","author":"P Auinger","year":"2003","unstructured":"Auinger P, Lanphear BP, Kalkwarf HJ, Mansour ME. Trends in otitis media among children in the United States. Pediatrics. 2003;112:514\u201320. https:\/\/doi.org\/10.1542\/peds.112.3.514.","journal-title":"Pediatrics"},{"key":"787_CR224","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-540-75418-3_6","volume-title":"Bacterial biofilms","author":"K Lewis","year":"2008","unstructured":"Lewis K. Multidrug tolerance of biofilms and persister cells. In: Romeo T, editor. Bacterial biofilms. Berlin: Springer; 2008. p. 107\u201331."},{"key":"787_CR225","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens5010002","volume":"5","author":"PD Olson","year":"2016","unstructured":"Olson PD, Hunstad DA. Subversion of host innate immunity by uropathogenic Escherichia coli. Pathogens. 2016;5:2. https:\/\/doi.org\/10.3390\/pathogens5010002.","journal-title":"Pathogens"},{"key":"787_CR226","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1128\/AEM.02636-13","volume":"79","author":"TK Wood","year":"2013","unstructured":"Wood TK, Knabel SJ, Kwan BW. Bacterial persister cell formation and dormancy. Appl Environ Microbiol. 2013;79:7116\u201321. https:\/\/doi.org\/10.1128\/AEM.02636-13.","journal-title":"Appl Environ Microbiol"},{"key":"787_CR227","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1137947","volume":"13","author":"A Zhao","year":"2023","unstructured":"Zhao A, Sun J, Liu Y. Understanding bacterial biofilms: from definition to treatment strategies. Front Cell Infect Microbiol. 2023;13:1137947. https:\/\/doi.org\/10.3389\/fcimb.2023.1137947.","journal-title":"Front Cell Infect Microbiol"},{"key":"787_CR228","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/mi.2011.27","volume":"4","author":"SD Goodman","year":"2011","unstructured":"Goodman SD, Obergfell KP, Jurcisek JA, et al. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol. 2011;4:625\u201337. https:\/\/doi.org\/10.1038\/mi.2011.27.","journal-title":"Mucosal Immunol"},{"key":"787_CR229","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/mmi.12735","volume":"93","author":"ME Brockson","year":"2014","unstructured":"Brockson ME, Novotny LA, Mokrzan EM, et al. Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms. Mol Microbiol. 2014;93:1246\u201358. https:\/\/doi.org\/10.1111\/mmi.12735.","journal-title":"Mol Microbiol"},{"key":"787_CR230","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ebiom.2016.06.022","volume":"10","author":"LA Novotny","year":"2016","unstructured":"Novotny LA, Jurcisek JA, Goodman SD, Bakaletz LO. Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo. EBioMedicine. 2016;10:33\u201344. https:\/\/doi.org\/10.1016\/j.ebiom.2016.06.022.","journal-title":"EBioMedicine"},{"key":"787_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102867","volume":"59","author":"LA Novotny","year":"2020","unstructured":"Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020;59:10.1016\/j.ebiom.2020.102867.","journal-title":"EBioMedicine"},{"key":"787_CR232","doi-asserted-by":"publisher","first-page":"E2698","DOI":"10.1002\/lary.29497","volume":"131","author":"LA Novotny","year":"2021","unstructured":"Novotny LA, Chiang T, Goodman SD, et al. Humanized anti-DNABII Fab fragments plus ofloxacin eradicated biofilms in experimental otitis media. Laryngoscope. 2021;131:E2698\u2013704. https:\/\/doi.org\/10.1002\/lary.29497.","journal-title":"Laryngoscope"},{"key":"787_CR233","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01877-21","volume":"66","author":"N Kurbatfinski","year":"2022","unstructured":"Kurbatfinski N, Goodman SD, Bakaletz LO. A humanized monoclonal antibody potentiates killing of diverse biofilm-forming respiratory tract pathogens by antibiotics. Antimicrob Agents Chemother. 2022;66:e01877-21. https:\/\/doi.org\/10.1128\/aac.01877-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioflm.2022.100096","volume":"4","author":"JA Jurcisek","year":"2022","unstructured":"Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022;4:100096. https:\/\/doi.org\/10.1016\/j.bioflm.2022.100096.","journal-title":"Biofilm"},{"key":"787_CR235","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40284-5","volume":"13","author":"KQ Wilbanks","year":"2023","unstructured":"Wilbanks KQ, Mokrzan EM, Kesler TM, et al. Nontypeable Haemophilus influenzae released from biofilm residence by monoclonal antibody directed against a biofilm matrix component display a vulnerable phenotype. Sci Rep. 2023;13:12959. https:\/\/doi.org\/10.1038\/s41598-023-40284-5.","journal-title":"Sci Rep"},{"key":"787_CR236","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03066-24","volume":"13","author":"N Kurbatfinski","year":"2025","unstructured":"Kurbatfinski N, Jurscisek JA, Wilbanks KQ, et al. Respiratory tract antimicrobial peptides more effectively killed multiple methicillin-resistant Staphylococcus aureus and nontypeable Haemophilus influenzae isolates after disruption from biofilm residence. Microbiol Spectr. 2025;13:e03066-24. https:\/\/doi.org\/10.1128\/spectrum.03066-24.","journal-title":"Microbiol Spectr"},{"key":"787_CR237","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11010104","volume":"11","author":"JV Rogers","year":"2022","unstructured":"Rogers JV, Hall VL, McOsker CC. Crumbling the castle: targeting DNABII proteins for collapsing bacterial biofilms as a therapeutic approach to treat disease and combat antimicrobial resistance. Antibiotics. 2022;11:104. https:\/\/doi.org\/10.3390\/antibiotics11010104.","journal-title":"Antibiotics"},{"key":"787_CR238","unstructured":"Clarametyx Biosciences, Inc. A 2-part first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of CMTX-101, an anti-DNABII monoclonal antibody, in healthy subjects (Part 1) and hospitalized subjects with suspected or confirmed community-acquired bacterial pneumonia of moderate severity (Part 2). 2024. clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR239","unstructured":"Clarametyx Biosciences, Inc. A phase 1b & 2a study to evaluate the safety of CMTX-101 in combination with inhaled antibiotics in people with cystic fibrosis chronically infected with Pseudomonas aeruginosa. 2025. clinicaltrials.gov. Accessed 20 May 2025."},{"key":"787_CR240","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1128\/aac.02588-15","volume":"60","author":"A Estell\u00e9s","year":"2016","unstructured":"Estell\u00e9s A, Woischnig A-K, Liu K, et al. A high-affinity native human antibody disrupts biofilm from Staphylococcus aureus bacteria and potentiates antibiotic efficacy in a mouse implant infection model. Antimicrob Agents Chemother. 2016;60:2292\u2013301. https:\/\/doi.org\/10.1128\/aac.02588-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR241","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00904-17","volume":"61","author":"YQ Xiong","year":"2017","unstructured":"Xiong YQ, Estell\u00e9s A, Li L, et al. A human biofilm-disrupting monoclonal antibody potentiates antibiotic efficacy in rodent models of both Staphylococcus aureus and Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2017;61:10.1128\/aac.00904-17. https:\/\/doi.org\/10.1128\/aac.00904-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR242","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12101490","volume":"12","author":"ZDC Burke","year":"2023","unstructured":"Burke ZDC, Hart CM, Kelley BV, et al. Monoclonal antibody disrupts biofilm structure and restores antibiotic susceptibility in an orthopedic implant infection model. Antibiotics. 2023;12:1490. https:\/\/doi.org\/10.3390\/antibiotics12101490.","journal-title":"Antibiotics"},{"key":"787_CR243","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00655-24","volume":"68","author":"J Conway","year":"2024","unstructured":"Conway J, Delanois RE, Mont MA, et al. Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. Antimicrob Agents Chemother. 2024;68:e00655-24. https:\/\/doi.org\/10.1128\/aac.00655-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR244","unstructured":"Trellis Bioscience LLC. Phase 2 study to evaluate the efficacy and safety of TRL1068 for the treatment of chronic prosthetic joint infection of the knee or hip without exchange arthroplasty. 2020. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2025."},{"key":"787_CR245","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/j.chembiol.2024.11.005","volume":"31","author":"JS Temme","year":"2024","unstructured":"Temme JS, Tan Z, Li M, et al. Insights into biofilm architecture and maturation enable improved clinical strategies for exopolysaccharide-targeting therapeutics. Cell Chem Biol. 2024;31:2096-111.e7. https:\/\/doi.org\/10.1016\/j.chembiol.2024.11.005.","journal-title":"Cell Chem Biol"},{"key":"787_CR246","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14685-3","volume":"11","author":"SA Tursi","year":"2020","unstructured":"Tursi SA, Puligedda RD, Szabo P, et al. Salmonella Typhimurium biofilm disruption by a human antibody that binds a pan-amyloid epitope on curli. Nat Commun. 2020;11:1007. https:\/\/doi.org\/10.1038\/s41467-020-14685-3.","journal-title":"Nat Commun"},{"key":"787_CR247","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.67301","volume":"11","author":"L de Vor","year":"2022","unstructured":"de Vor L, van Dijk B, van Kessel K, et al. Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm. Elife. 2022;11:e67301. https:\/\/doi.org\/10.7554\/eLife.67301.","journal-title":"Elife"},{"key":"787_CR248","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","volume":"362","author":"NS Laursen","year":"2018","unstructured":"Laursen NS, Friesen RHE, Zhu X, et al. Universal protection against influenza infection by a multi-domain antibody to influenza hemagglutinin. Science. 2018;362:598\u2013602. https:\/\/doi.org\/10.1126\/science.aaq0620.","journal-title":"Science"},{"key":"787_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60250-1","volume":"16","author":"S De Cae","year":"2025","unstructured":"De Cae S, Van Molle I, van Schie L, et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. Nat Commun. 2025;16:5040. https:\/\/doi.org\/10.1038\/s41467-025-60250-1.","journal-title":"Nat Commun"},{"key":"787_CR250","doi-asserted-by":"publisher","first-page":"114726","DOI":"10.1016\/j.addr.2023.114726","volume":"195","author":"J Kim","year":"2023","unstructured":"Kim J, Yong J, Sang Z, Xiang Y, et al. Nanobodies: robust miniprotein binders in biomedicine. Adv Drug Deliv Rev. 2023;195:114726. https:\/\/doi.org\/10.1016\/j.addr.2023.114726.","journal-title":"Adv Drug Deliv Rev"},{"key":"787_CR251","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1128\/IAI.01033-13","volume":"81","author":"JM Tremblay","year":"2013","unstructured":"Tremblay JM, Mukherjee J, Leysath CE, et al. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun. 2013;81:4592\u2013603. https:\/\/doi.org\/10.1128\/IAI.01033-13.","journal-title":"Infect Immun"},{"key":"787_CR252","doi-asserted-by":"publisher","first-page":"21596","DOI":"10.1074\/jbc.M116.749184","volume":"291","author":"CE Vrentas","year":"2016","unstructured":"Vrentas CE, Moayeri M, Keefer AB, et al. A diverse set of single-domain antibodies (VHHs) against the anthrax toxin lethal and edema factors provides a basis for construction of a bispecific agent that protects against anthrax infection. J Biol Chem. 2016;291:21596\u2013606. https:\/\/doi.org\/10.1074\/jbc.M116.749184.","journal-title":"J Biol Chem"},{"key":"787_CR253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1995-7645(10)60020-X","volume":"3","author":"P Jangra","year":"2010","unstructured":"Jangra P, Singh A. Staphylococcus aureus \u03b2-hemolysin-neutralizing single-domain antibody isolated from phage display library of Indian desert camel. Asian Pac J Trop Med. 2010;3:1\u20137. https:\/\/doi.org\/10.1016\/S1995-7645(10)60020-X.","journal-title":"Asian Pac J Trop Med"},{"key":"787_CR254","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1074\/jbc.M110.198754","volume":"286","author":"G Hussack","year":"2011","unstructured":"Hussack G, Arbabi-Ghahroudi M, van Faassen H, et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem. 2011;286:8961\u201376. https:\/\/doi.org\/10.1074\/jbc.M110.198754.","journal-title":"J Biol Chem"},{"key":"787_CR255","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/infdis\/jiu196","volume":"210","author":"Z Yang","year":"2014","unstructured":"Yang Z, Schmidt D, Liu W, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis. 2014;210:964\u201372. https:\/\/doi.org\/10.1093\/infdis\/jiu196.","journal-title":"J Infect Dis"},{"key":"787_CR256","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011496","volume":"19","author":"SL Kordus","year":"2023","unstructured":"Kordus SL, Kroh HK, Rodr\u00edguez RC, et al. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo. PLoS Pathog. 2023;19:e1011496. https:\/\/doi.org\/10.1371\/journal.ppat.1011496.","journal-title":"PLoS Pathog"},{"key":"787_CR257","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208978","volume":"13","author":"G Hussack","year":"2018","unstructured":"Hussack G, Ryan S, van Faassen H, et al. Neutralization of Clostridium difficile toxin B with VHH-Fc fusions targeting the delivery and CROPs domains. PLoS ONE. 2018;13:e0208978. https:\/\/doi.org\/10.1371\/journal.pone.0208978.","journal-title":"PLoS ONE"},{"key":"787_CR258","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1128\/CVI.00730-15","volume":"23","author":"DJ Schmidt","year":"2016","unstructured":"Schmidt DJ, Beamer G, Tremblay JM, et al. A tetraspecific VHH-based neutralizing antibody modifies disease outcome in three animal models of Clostridium difficile infection. Clin Vaccine Immunol. 2016;23:774\u201384. https:\/\/doi.org\/10.1128\/CVI.00730-15.","journal-title":"Clin Vaccine Immunol"},{"key":"787_CR259","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978858","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen B, Perry K, Jin R. Neutralizing epitopes on Clostridioides difficile toxin A revealed by the structures of two camelid VHH antibodies. Front Immunol. 2022;13:978858. https:\/\/doi.org\/10.3389\/fimmu.2022.978858.","journal-title":"Front Immunol"},{"key":"787_CR260","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1128\/IAI.00870-15","volume":"84","author":"KK Andersen","year":"2016","unstructured":"Andersen KK, Strokappe NM, Hultberg A, et al. Neutralization of Clostridium difficile toxin B mediated by engineered lactobacilli that produce single-domain antibodies. Infect Immun. 2016;84:395\u2013406. https:\/\/doi.org\/10.1128\/IAI.00870-15.","journal-title":"Infect Immun"},{"key":"787_CR261","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax4905","volume":"12","author":"K Chen","year":"2020","unstructured":"Chen K, Zhu Y, Zhang Y, et al. A probiotic yeast-based immunotherapy against Clostridioides difficile infection. Sci Transl Med. 2020;12:eaax4905. https:\/\/doi.org\/10.1126\/scitranslmed.aax4905.","journal-title":"Sci Transl Med"},{"key":"787_CR262","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1128\/CVI.00107-06","volume":"13","author":"M El Khattabi","year":"2006","unstructured":"El Khattabi M, Adams H, Heezius E, et al. Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications. Clin Vaccine Immunol. 2006;13:1079\u201386. https:\/\/doi.org\/10.1128\/CVI.00107-06.","journal-title":"Clin Vaccine Immunol"},{"key":"787_CR263","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1007\/s00253-012-4518-x","volume":"97","author":"W Ebrahimizadeh","year":"2013","unstructured":"Ebrahimizadeh W, Mousavi Gargari S, Rajabibazl M, et al. Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol. 2013;97:4457\u201366. https:\/\/doi.org\/10.1007\/s00253-012-4518-x.","journal-title":"Appl Microbiol Biotechnol"},{"key":"787_CR264","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.129208","volume":"259","author":"M Mei","year":"2024","unstructured":"Mei M, Lu M, Li S, et al. Development of nanobodies specific to clumping factors A of Staphylococcus aureus by yeast surface display. Int J Biol Macromol. 2024;259:129208. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.129208.","journal-title":"Int J Biol Macromol"},{"key":"787_CR265","unstructured":"AstraZeneca. A phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end-stage kidney disease receiving hemodialysis through a central venous catheter. 2025. https:\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR266","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell AC, Wang X, Kade\u0159\u00e1bkov\u00e1 N, et al Resurfacing promotes antibacterial activity of a lipid A-binding nanobody. Proc Natl Acad Sci USA. 122:e2509305122.","DOI":"10.1073\/pnas.2509305122"},{"key":"787_CR267","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1021\/bc025536.j","volume":"13","author":"GM Dubowchik","year":"2002","unstructured":"Dubowchik GM, Firestone RA, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002;13:855\u201369. https:\/\/doi.org\/10.1021\/bc025536.j.","journal-title":"Bioconjug Chem"},{"key":"787_CR268","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature16057","volume":"527","author":"SM Lehar","year":"2015","unstructured":"Lehar SM, Pillow T, Xu M, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature. 2015;527:323\u20138. https:\/\/doi.org\/10.1038\/nature16057.","journal-title":"Nature"},{"key":"787_CR269","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/13543776.2017.1259411","volume":"27","author":"PMSD Cal","year":"2017","unstructured":"Cal PMSD, Matos MJ, Bernardes GJL. Trends in therapeutic drug conjugates for bacterial diseases: a patent review. Expert Opin Ther Pat. 2017;27:179\u201389. https:\/\/doi.org\/10.1080\/13543776.2017.1259411.","journal-title":"Expert Opin Ther Pat"},{"key":"787_CR270","doi-asserted-by":"publisher","first-page":"e02588","DOI":"10.1128\/AAC.02588-18","volume":"63","author":"M Peck","year":"2019","unstructured":"Peck M, Rothenberg ME, Deng R, et al. A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and oharmacokinetics of DSTA4637S, an anti-Staphylococcus aureus Thiomab antibody-antibiotic conjugate, in healthy volunteers. Antimicrob Agents Chemother. 2019;63:e02588-e2618. https:\/\/doi.org\/10.1128\/AAC.02588-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"787_CR271","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.477","volume":"7","author":"J Lim","year":"2020","unstructured":"Lim J, Lewin-Koh N, Chu T, et al. 167. A phase 1b, randomized, double-blind, placebo-controlled, multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S in patients with Staphylococcus aureus bacteremia receiving standard-of-care antibiotics. Open Forum Infect Dis. 2020;7:S213. https:\/\/doi.org\/10.1093\/ofid\/ofaa439.477.","journal-title":"Open Forum Infect Dis"},{"key":"787_CR272","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1080\/19420862.2016.1229722","volume":"8","author":"C Zhou","year":"2016","unstructured":"Zhou C, Lehar S, Gutierrez J, et al. Pharmacokinetics and pharmacodynamics of DSTA4637A: a novel Thiomab\u2122 antibody antibiotic conjugate against Staphylococcus aureus in mice. MAbs. 2016;8:1612\u20139. https:\/\/doi.org\/10.1080\/19420862.2016.1229722.","journal-title":"MAbs"},{"key":"787_CR273","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1080\/19420862.2019.1627152","volume":"11","author":"R Deng","year":"2019","unstructured":"Deng R, Zhou C, Li D, et al. Preclinical and translational pharmacokinetics of a novel Thiomab\u2122 antibody-antibiotic conjugate against Staphylococcus aureus. MAbs. 2019;11:1162\u201374. https:\/\/doi.org\/10.1080\/19420862.2019.1627152.","journal-title":"MAbs"},{"key":"787_CR274","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jare.2023.12.001","volume":"65","author":"L Qin","year":"2023","unstructured":"Qin L, Hu N, Zhang Y, et al. Antibody-antibiotic conjugate targeted therapy for orthopedic implant-associated intracellular S. aureus infections. J Adv Res. 2023;65:239\u201355. https:\/\/doi.org\/10.1016\/j.jare.2023.12.001.","journal-title":"J Adv Res"},{"key":"787_CR275","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00202-21","volume":"12","author":"KK Kajihara","year":"2021","unstructured":"Kajihara KK, Pantua H, Hernandez-Barry H, et al. Potent killing of Pseudomonas aeruginosa by an antibody-antibiotic conjugate. MBio. 2021;12:e00202-21. https:\/\/doi.org\/10.1128\/mBio.00202-21.","journal-title":"MBio"},{"key":"787_CR276","doi-asserted-by":"crossref","unstructured":"Lavender H, Barendt TA, Lucy D, Tang CM. An antibody-drug conjugate exploiting a bacterial immune evasion mechanism is effective against multidrug resistant Neisseria gonorrhoeae. 2025;2025.04.16.644158.","DOI":"10.1101\/2025.04.16.644158"},{"key":"787_CR277","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","volume":"17","author":"L Van Hoecke","year":"2019","unstructured":"Van Hoecke L, Roose K. How mRNA therapeutics are entering the monoclonal antibody field. J Transl Med. 2019;17:54. https:\/\/doi.org\/10.1186\/s12967-019-1804-8.","journal-title":"J Transl Med"},{"key":"787_CR278","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31:317\u201334. https:\/\/doi.org\/10.1007\/s40259-017-0234-5.","journal-title":"BioDrugs"},{"key":"787_CR279","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","volume":"34","author":"A Patel","year":"2020","unstructured":"Patel A, Bah MA, Weiner DB. In vivo delivery of nucleic acid-encoded monoclonal antibodies. BioDrugs. 2020;34:273\u201393. https:\/\/doi.org\/10.1007\/s40259-020-00412-3.","journal-title":"BioDrugs"},{"key":"787_CR280","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2017","unstructured":"Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2017;8:87\u2013104. https:\/\/doi.org\/10.1016\/j.omtm.2017.11.007.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"787_CR281","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122:23\u201336. https:\/\/doi.org\/10.1182\/blood-2013-01-306647.","journal-title":"Blood"},{"key":"787_CR282","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"S Daya","year":"2008","unstructured":"Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21:583\u201393. https:\/\/doi.org\/10.1128\/CMR.00008-08.","journal-title":"Clin Microbiol Rev"},{"key":"787_CR283","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","volume":"358","author":"AM Maguire","year":"2008","unstructured":"Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis. N Engl J Med. 2008;358:2240\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0802315.","journal-title":"N Engl J Med"},{"key":"787_CR284","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1706198.","journal-title":"N Engl J Med"},{"key":"787_CR285","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40265-023-01845-0","volume":"83","author":"Y-A Heo","year":"2023","unstructured":"Heo Y-A. Etranacogene dezaparvovec: first approval. Drugs. 2023;83:347\u201352. https:\/\/doi.org\/10.1007\/s40265-023-01845-0.","journal-title":"Drugs"},{"key":"787_CR286","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene moxeparvovec: first approval. Drugs. 2023;83:1323\u20139. https:\/\/doi.org\/10.1007\/s40265-023-01929-x.","journal-title":"Drugs"},{"key":"787_CR287","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/infdis\/jix644","volume":"217","author":"LP van Lieshout","year":"2018","unstructured":"van Lieshout LP, Soule G, Sorensen D, et al. Intramuscular adeno-associated virus-mediated expression of monoclonal antibodies provides 100% protection against Ebola virus infection in mice. J Infect Dis. 2018;217:916\u201325. https:\/\/doi.org\/10.1093\/infdis\/jix644.","journal-title":"J Infect Dis"},{"key":"787_CR288","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","volume":"50","author":"JM Martinez-Navio","year":"2019","unstructured":"Martinez-Navio JM, Fuchs SP, Pantry SN, et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity. 2019;50:567-75.e5. https:\/\/doi.org\/10.1016\/j.immuni.2019.02.005.","journal-title":"Immunity"},{"key":"787_CR289","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00449","volume":"11","author":"JM Martinez-Navio","year":"2020","unstructured":"Martinez-Navio JM, Fuchs SP, Mendes DE, et al. Long-term delivery of an anti-SIV monoclonal antibody with AAV. Front Immunol. 2020;11:449. https:\/\/doi.org\/10.3389\/fimmu.2020.00449.","journal-title":"Front Immunol"},{"key":"787_CR290","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.mt.6300344","volume":"16","author":"BP De","year":"2008","unstructured":"De BP, Hackett NR, Crystal RG, Boyer JL. Rapid\/sustained anti-anthrax passive immunity mediated by co-administration of Ad\/AAV. Mol Ther. 2008;16:203\u20139. https:\/\/doi.org\/10.1038\/sj.mt.6300344.","journal-title":"Mol Ther"},{"key":"787_CR291","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41434-021-00236-y","volume":"30","author":"MM Guilleman","year":"2023","unstructured":"Guilleman MM, Stevens BAY, Van Lieshout LP, et al. AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge. Gene Ther. 2023;30:455\u201362. https:\/\/doi.org\/10.1038\/s41434-021-00236-y.","journal-title":"Gene Ther"},{"key":"787_CR292","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41434-024-00453-1","volume":"31","author":"JA Lopes","year":"2024","unstructured":"Lopes JA, Garnier NE, Pei Y, et al. AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia. Gene Ther. 2024;31:400\u201312. https:\/\/doi.org\/10.1038\/s41434-024-00453-1.","journal-title":"Gene Ther"},{"key":"787_CR293","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.960937","author":"AA Derkaev","year":"2022","unstructured":"Derkaev AA, Ryabova EI, Esmagambetov IB, et al. rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis. Front Microbiol. 2022. https:\/\/doi.org\/10.3389\/fmicb.2022.960937.","journal-title":"Front Microbiol"},{"key":"787_CR294","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy FH, Lewis DJM, Gelderblom HC, et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV. 2019;6:e230\u20139. https:\/\/doi.org\/10.1016\/S2352-3018(19)30003-7.","journal-title":"Lancet HIV"},{"key":"787_CR295","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.omtm.2019.11.010","volume":"16","author":"SP Fuchs","year":"2019","unstructured":"Fuchs SP, Martinez-Navio JM, Rakasz EG, et al. Liver-directed but not muscle-directed AAV-antibody gene transfer limits humoral immune responses in Rhesus monkeys. Mol Ther Methods Clin Dev. 2019;16:94\u2013102. https:\/\/doi.org\/10.1016\/j.omtm.2019.11.010.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"787_CR296","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1128\/JVI.78.12.6344-6359.2004","volume":"78","author":"CS Peden","year":"2004","unstructured":"Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol. 2004;78:6344\u201359. https:\/\/doi.org\/10.1128\/JVI.78.12.6344-6359.2004.","journal-title":"J Virol"},{"key":"787_CR297","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.217","volume":"31","author":"PB Shieh","year":"2020","unstructured":"Shieh PB, B\u00f6nnemann CG, M\u00fcller-Felber W, et al. Re: \u201cMoving forward after two deaths in a gene therapy trial of myotubular myopathy\u201d by Wilson and Flotte. Hum Gene Ther. 2020;31:787. https:\/\/doi.org\/10.1089\/hum.2020.217.","journal-title":"Hum Gene Ther"},{"key":"787_CR298","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991832","volume":"13","author":"X Li","year":"2022","unstructured":"Li X, Wei X, Lin J, Ou L. A versatile toolkit for overcoming AAV immunity. Front Immunol. 2022;13:991832. https:\/\/doi.org\/10.3389\/fimmu.2022.991832.","journal-title":"Front Immunol"},{"key":"787_CR299","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247:1465\u20138. https:\/\/doi.org\/10.1126\/science.1690918.","journal-title":"Science"},{"key":"787_CR300","doi-asserted-by":"publisher","DOI":"10.3390\/antib12030046","volume":"12","author":"C Chung","year":"2023","unstructured":"Chung C, Kudchodkar SB, Chung CN, et al. Expanding the reach of monoclonal antibodies: a review of synthetic nucleic acid delivery in immunotherapy. Antibodies. 2023;12:46. https:\/\/doi.org\/10.3390\/antib12030046.","journal-title":"Antibodies"},{"key":"787_CR301","doi-asserted-by":"publisher","DOI":"10.1186\/1479-0556-2-2","volume":"2","author":"N Perez","year":"2004","unstructured":"Perez N, Bigey P, Scherman D, et al. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther. 2004;2:2. https:\/\/doi.org\/10.1186\/1479-0556-2-2.","journal-title":"Genet Vaccines Ther"},{"key":"787_CR302","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/sj.gt.3301522","volume":"8","author":"JM McMahon","year":"2001","unstructured":"McMahon JM, Signori E, Wells KE, et al. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase: increased expression with reduced muscle damage. Gene Ther. 2001;8:1264\u201370. https:\/\/doi.org\/10.1038\/sj.gt.3301522.","journal-title":"Gene Ther"},{"key":"787_CR303","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00576-7","volume":"8","author":"A Patel","year":"2017","unstructured":"Patel A, DiGiandomenico A, Keller AE, et al. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nat Commun. 2017;8:637. https:\/\/doi.org\/10.1038\/s41467-017-00576-7.","journal-title":"Nat Commun"},{"key":"787_CR304","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0020-x","volume":"2","author":"STC Elliott","year":"2017","unstructured":"Elliott STC, Kallewaard NL, Benjamin E, et al. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections. npj Vaccines. 2017;2:18. https:\/\/doi.org\/10.1038\/s41541-017-0020-x.","journal-title":"npj Vaccines"},{"key":"787_CR305","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33309-6","volume":"13","author":"EM Parzych","year":"2022","unstructured":"Parzych EM, Du J, Ali AR, et al. DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. Nat Commun. 2022;13:5886. https:\/\/doi.org\/10.1038\/s41467-022-33309-6.","journal-title":"Nat Commun"},{"key":"787_CR306","unstructured":"Tebas P. A phase 1, open-label, single center, dose escalation study of the safety and pharmacokinetics of mAb AZD5396 and mAb AZD8076 delivered as dMAbs in healthy adults. 2025. https:\/\/clinicaltrials.gov. Accessed 20 May 2026."},{"issue":"12","key":"787_CR307","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1038\/s41591-025-03969-0","volume":"31","author":"P Tebas","year":"2025","unstructured":"Tebas P, Patel A, Agnes JT, et al. Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial. Nat Med. 2025;31(12):4150\u20139. https:\/\/doi.org\/10.1038\/s41591-025-03969-0.","journal-title":"Nat Med"},{"key":"787_CR308","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04553-1","volume":"21","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Gan L, Ke D, et al. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy. J Transl Med. 2023;21:693. https:\/\/doi.org\/10.1186\/s12967-023-04553-1.","journal-title":"J Transl Med"},{"key":"787_CR309","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz H, Atochina-Vasserman EN, Weissman D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet. 2024;403:1192\u2013204. https:\/\/doi.org\/10.1016\/S0140-6736(23)02444-3.","journal-title":"Lancet"},{"key":"787_CR310","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang L, Lin A, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621:396\u2013403. https:\/\/doi.org\/10.1038\/s41586-023-06127-z.","journal-title":"Nature"},{"key":"787_CR311","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102648","volume":"36","author":"A Medjmedj","year":"2025","unstructured":"Medjmedj A, Genon H, Hezili D, et al. Evaluation of synthetic mRNA with selected UTR sequences and alternative poly(A) tail, in vitro and in vivo. Mol Ther Nucleic Acids. 2025;36:102648. https:\/\/doi.org\/10.1016\/j.omtn.2025.102648.","journal-title":"Mol Ther Nucleic Acids"},{"key":"787_CR312","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf861","volume":"53","author":"L Wang","year":"2025","unstructured":"Wang L, Liu S, Huang J, et al. Machine learning-based analysis of the impact of 5\u2032 untranslated region on protein expression. Nucleic Acids Res. 2025;53:gkaf861. https:\/\/doi.org\/10.1093\/nar\/gkaf861.","journal-title":"Nucleic Acids Res"},{"key":"787_CR313","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi N, Secreto AJ, Shan X, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630. https:\/\/doi.org\/10.1038\/ncomms14630.","journal-title":"Nat Commun"},{"key":"787_CR314","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.15252\/emmm.201707678","volume":"9","author":"M Thran","year":"2017","unstructured":"Thran M, Mukherjee J, P\u00f6nisch M, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9:1434\u201347. https:\/\/doi.org\/10.15252\/emmm.201707678.","journal-title":"EMBO Mol Med"},{"key":"787_CR315","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw6647","volume":"4","author":"N Kose","year":"2019","unstructured":"Kose N, Fox JM, Sapparapu G, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against Chikungunya infection. Sci Immunol. 2019;4:eaaw6647. https:\/\/doi.org\/10.1126\/sciimmunol.aaw6647.","journal-title":"Sci Immunol"},{"key":"787_CR316","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","volume":"32","author":"Y-Q Deng","year":"2022","unstructured":"Deng Y-Q, Zhang N-N, Zhang Y-F, et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 2022;32:375\u201382. https:\/\/doi.org\/10.1038\/s41422-022-00630-0.","journal-title":"Cell Res"},{"key":"787_CR317","doi-asserted-by":"publisher","DOI":"10.3390\/antib11040067","volume":"11","author":"E Narayanan","year":"2022","unstructured":"Narayanan E, Falcone S, Elbashir SM, et al. Rational design and in vivo characterization of mRNA-encoded broadly neutralizing antibody combinations against HIV-1. Antibodies. 2022;11:67. https:\/\/doi.org\/10.3390\/antib11040067.","journal-title":"Antibodies"},{"key":"787_CR318","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.ymthe.2024.05.036","volume":"32","author":"C Tkaczyk","year":"2024","unstructured":"Tkaczyk C, Newton M, Patnaik MM, et al. In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection. Mol Ther. 2024;32:2505\u201318. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.036.","journal-title":"Mol Ther"},{"key":"787_CR319","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41092-7","volume":"13","author":"M Thran","year":"2023","unstructured":"Thran M, P\u00f6nisch M, Danz H, et al. Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies. Sci Rep. 2023;13:14632. https:\/\/doi.org\/10.1038\/s41598-023-41092-7.","journal-title":"Sci Rep"},{"key":"787_CR320","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101253","volume":"4","author":"CE Deal","year":"2023","unstructured":"Deal CE, Richards AF, Yeung T, et al. An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions. Cell Rep Med. 2023;4:101253. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101253.","journal-title":"Cell Rep Med"},{"key":"787_CR321","unstructured":"ModernaTX, Inc. A phase 1, randomized, placebo-controlled, dose ranging study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-1944, encoding for an anti-Chikungunya virus monoclonal antibody, in healthy adults. 2021. https\/\/www.clinicaltrials.gov. Accessed 20 May 2026."},{"key":"787_CR322","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August A, Attarwala HZ, Himansu S, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021;27:2224\u201333. https:\/\/doi.org\/10.1038\/s41591-021-01573-6.","journal-title":"Nat Med"},{"key":"787_CR323","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-026-00147-5","volume":"12","author":"Z Wang","year":"2026","unstructured":"Wang Z, Cheng B, Tkaczyk C, et al. Lyophilized monoclonal antibody (mAb) encoded mRNA-lipid nanoparticles (LNPs) lead to stable in vivo expression of mAb after room temperature storage. AAPS Open. 2026;12:12. https:\/\/doi.org\/10.1186\/s41120-026-00147-5.","journal-title":"AAPS Open"},{"key":"787_CR324","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/imr.13427","volume":"328","author":"R Martineau","year":"2024","unstructured":"Martineau R, Susini S, Marabelle A. Fc effector function of immune checkpoint blocking antibodies in oncology. Immunol Rev. 2024;328:334\u201349. https:\/\/doi.org\/10.1111\/imr.13427.","journal-title":"Immunol Rev"},{"key":"787_CR325","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46321-9","volume":"15","author":"S Foss","year":"2024","unstructured":"Foss S, Sakya SA, Aguinagalde L, et al. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 2024;15:2007. https:\/\/doi.org\/10.1038\/s41467-024-46321-9.","journal-title":"Nat Commun"},{"key":"787_CR326","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","volume":"35","author":"S Ko","year":"2021","unstructured":"Ko S, Jo M, Jung ST. Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering. BioDrugs. 2021;35:147\u201357. https:\/\/doi.org\/10.1007\/s40259-021-00471-0.","journal-title":"BioDrugs"},{"key":"787_CR327","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1080\/21645515.2021.1985891","volume":"17","author":"DH Nawab","year":"2021","unstructured":"Nawab DH. Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects. Hum Vaccines Immunother. 2021;17:5532\u201345. https:\/\/doi.org\/10.1080\/21645515.2021.1985891.","journal-title":"Hum Vaccines Immunother"},{"key":"787_CR328","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2021.03.009","volume":"54","author":"BM Gunn","year":"2021","unstructured":"Gunn BM, Lu R, Slein MD, et al. A Fc-engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity. 2021;54:815-28.e5. https:\/\/doi.org\/10.1016\/j.immuni.2021.03.009.","journal-title":"Immunity"},{"key":"787_CR329","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2023.108201","volume":"67","author":"M Garc\u00eda-Alija","year":"2023","unstructured":"Garc\u00eda-Alija M, van Moer B, Sastre DE, et al. Modulating antibody effector functions by Fc glycoengineering. Biotechnol Adv. 2023;67:108201. https:\/\/doi.org\/10.1016\/j.biotechadv.2023.108201.","journal-title":"Biotechnol Adv"},{"key":"787_CR330","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/0161-5890(87)90080-0","volume":"24","author":"L Bj\u00f6rck","year":"1987","unstructured":"Bj\u00f6rck L, Kastern W, Lindahl G, Wideb\u00e4ck K. Streptococcal protein G, expressed by streptococci or by Escherichia coli, has separate binding sites for human albumin and IgG. Mol Immunol. 1987;24:1113\u201322. https:\/\/doi.org\/10.1016\/0161-5890(87)90080-0.","journal-title":"Mol Immunol"},{"key":"787_CR331","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson JL, Juergens D, Bennett NR, et al. De novo design of protein structure and function with RFdiffusion. Nature. 2023;620:1089\u2013100. https:\/\/doi.org\/10.1038\/s41586-023-06415-8.","journal-title":"Nature"},{"key":"787_CR332","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41586-025-09721-5","volume":"649","author":"NR Bennett","year":"2026","unstructured":"Bennett NR, Watson JL, Ragotte RJ, et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature. 2026;649:183\u201393. https:\/\/doi.org\/10.1038\/s41586-025-09721-5.","journal-title":"Nature"},{"key":"787_CR333","doi-asserted-by":"publisher","unstructured":"Frontiers. Applying computational protein design to therapeutic antibody discovery: current state and perspectives. https:\/\/doi.org\/10.3389\/fimmu.2025.1571371\/full#h1. Accessed 23 Apr 2026.","DOI":"10.3389\/fimmu.2025.1571371\/full#h1"},{"key":"787_CR334","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41401-024-01380-y","volume":"46","author":"X He","year":"2025","unstructured":"He X, Li J, Xu J, et al. AI-driven antibody design with generative diffusion models: current insights and future directions. Acta Pharmacol Sin. 2025;46:565\u201374. https:\/\/doi.org\/10.1038\/s41401-024-01380-y.","journal-title":"Acta Pharmacol Sin"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00787-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:38:42Z","timestamp":1783330722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00787-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":334,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00787-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"11 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E. Antonio DiGiandomenico, Christine Tkaczyk, Alexander B. Smith, Michael P. Doyle, Timothy J. Break, and Galit Alter are employees of AstraZeneca and may hold stock in the company. Matthew J. Slarve, Brian Luna, and Brad Spellberg have no conflict of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This article has no associated primary data, and therefore no data will be deposited.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MS: conceptualization, literature review, writing, copy editing. CT: literature review, writing, copy editing. MD: literature review, writing. TB: literature review, writing. AS: literature review,  writing. GA: literature review, writing. BL: conceptualization, copy editing. BS: conceptualization, copy editing. ADiG: conceptualization, literature review, writing, copy editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}